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Summary
Evidence from multiple lines of research supports the hypothesis that schizo-
phrenia arises from interactions between genetic and environmental factors
during critical early periods of neuronal development.
Abnormal levels of thyroid hormones or retinoids during fetal development
have been suggested to contribute to the neurodevelopmental deviations found
in schizophrenic patients. In fact, thyroid hormones and retinoids could consti-
tute a functional link between genetic and environmental risk factors in schizo-
phrenia. This is an attractive hypothesis capable of explaining several epi-
demiological features of the disease.
Thyroid hormones and retinoids are involved in the regulation of central
nervous system function probably through their capacity to modulate the ex-
pression of several genes. To investigate if genes involved in the metabolism
of thyroid hormones and retinoids account for an increase in schizophrenia
susceptibility, we performed association studies in four promising candidate
genes, using three independent samples. The proteins encoded by these four
genes are involved in molecular pathways implicated in schizophrenia.
Human Nur-related receptor 1 (NR4A2) is an orphan nuclear receptor that
regulates transcription by heterodimerization with retinoid nuclear receptors.
NR4A2 is essential for the formation of the dopaminergic system, the neuro-
transmitter pathway targeted by most anti-psychotic drugs used in the treat-
ment of schizophrenia. We did not find, in our samples, any of the NR4A2
mutations previously described, further confirming that they are rare.
The Lipocalin-type of prostaglandin D2 synthase (PTGDS) transports thy-
roid hormones and retinoids, and the expression of the gene is regulated by
both modulators. In addition, it is involved in lipid metabolism, which is altered
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in schizophrenia. We found four previously described polymorphisms, none of
which was associated with schizophrenia.
Transthyretin (TTR) is a transporter of both thyroid hormones and retinoids,
and has been implicated in behavior. Neither a novel polymorphism, that we
describe for the first time, nor another, previously identified, were associated
to the disease. Similarly, serum TTR levels did not differ between patients and
mentally healthy individuals.
Neurogranin (NRGN) is a neurospecific protein whose expression is regu-
lated by retinoids and thyroid hormones. Interestingly, NRGN is involved in glu-
tamatergic transmission, known to be abnormal in schizophrenia. We report
the association of a DNA variant near the thyroid hormone response element
in the NRGN gene with schizophrenia in males. The gender specificity of this
association is of particular interest since significant symptomatic differences
in disease manifestation exist between sexes, such as earlier onset and more
severe manifestation in male patients. NRGN joins several other genes al-
ready implicated in schizophrenia that are likewise involved in the glutamater-
gic pathway, such as dysbindin and neuregulin. Thus, our finding introduces
an additional player into the glutamatergic hypothesis of schizophrenia.
In a preliminary study, we evaluated thyroid hormone function in schizo-
phrenic patients, which showed reduced levels of free triiodothyronine in males
when compared with healthy individuals. Whether this alteration is related to
the manifestation of symptoms still needs to be investigated.
Together our data support the involvement of thyroid hormones in schizo-
phrenia, which should be further explored in expression studies.
Resumo
Va´rios estudos sugerem que a esquizofrenia resulta da interacc¸a˜o entre fac-
tores ambientais e gene´ticos particularmente em perı´odos crı´ticos do desen-
volvimento do sistema nervoso central. Os factores ambientais podem condi-
cionar o desenvolvimento do sistema nervoso central, nomeadamente por
influenciarem a expressa˜o de va´rios genes. Tal e´ o caso, directa ou indi-
rectamente, da vitamina A e das hormonas tiroideias. Desta forma, estas
mole´culas podem estabelecer uma ponte entre genes e ambiente em es-
quizofrenia. Esta hipo´tese e´ particularmente atractiva por ser capaz de ex-
plicar va´rias caracterı´sticas da esquizofrenia, tais como a sua distribuic¸a˜o epi-
demiolo´gica. Com o intuito de testar se genes envolvidos no metabolismo
quer dos retino´ides quer das hormonas tiroideias contribuem para um au-
mento da susceptibilidade a` esquizofrenia, efectua´mos estudos de associac¸a˜o
em treˆs amostras independentes de doentes. Os genes escolhidos codifi-
cam proteı´nas que fazem parte de cascatas moleculares potencialmente rela-
cionadas com a esquizofrenia.
O NR4A2 e´ um receptor o´rfa˜o que, em parceria com receptores do a´cido
retino´ico, regula a transcric¸a˜o de va´rios genes. Sabe-se que o NR4A2 e´
essencial na formac¸a˜o do sistema dopamine´rgico, que e´ a via de neurotrans-
missores alvo da maioria dos fa´rmacos antipsico´ticos. Nas amostras que es-
tuda´mos, na˜o foi detectada nenhuma das mutac¸o˜es pre´viamente descritas no
gene da NR4A2, o que confirma serem mutac¸o˜es extremamente raras.
A expressa˜o do gene que codifica a PTGDS, uma proteı´na que transporta
tanto retino´ides como hormonas tiroideias, e´ regulada por ambos os ligandos.
Para ale´m disso, sendo responsa´vel pela produc¸a˜o de prostano´ides, esta´ en-
volvido no metabolismo lipı´dico que se sabe estar alterado em doentes com
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esquizofrenia. A pesquisa de mutac¸o˜es revelou apenas quatro polimorfismos
ja´ descritos na literatura, na˜o estando nenhum deles associado com a doenc¸a.
Os nı´veis de TTR, principal transportadora tanto de retino´ides como de
hormonas tiroideias, teˆm sido descritos como estando diminuı´dos em doentes
neurolo´gicos e psiquia´tricos, e a abolic¸a˜o da expressa˜o do gene como tendo
consequeˆncias no comportamento. Neste trabalho pesquisa´mos variantes
na TTR tendo identificado um novo polimorfismo. Nem este, nem um outro
pre´viamente descrito, se encontram no entanto associados com a esquizofre-
nia. De igual modo, os nı´veis se´ricos de TTR sa˜o ideˆnticos entre os doentes
e os indivı´duos mentalmente sauda´veis.
Estuda´mos, ainda, o gene que codifica a neurogranina (NRGN) cuja ex-
pressa˜o e´ regulada tanto por retino´ides como por hormonas tiroideias. A neu-
rogranina e´ uma proteı´na especı´fica dos neuro´nios e esta´ envolvida na trans-
missa˜o glutamate´rgica que se sabe estar alterada em doentes esquizofre´nicos.
Encontra´mos associac¸a˜o de um polimorfismo que se encontra pro´ximo do
elemento de resposta a`s hormonas tiroideias, em homens com esquizofre-
nia. A especificidade desta associac¸a˜o em homens e´ particularmente interes-
sante, uma vez que esta˜o descritas diferenc¸as na idade de inı´cio, gravidade
da doenc¸a e resposta ao tratamento entre homens e mulheres; sendo que nos
homens ha´ um inı´cio mais precoce e uma forma mais severa da manifestac¸a˜o
dos sintomas. Assim sendo, descrevemos, pela primeira vez, a NRGN como
mais um gene que confere aumento da susceptibilidade para a esquizofrenia.
De realc¸ar que a NRGN se encontra tanto a montante como a jusante de vias
de sinalizac¸a˜o pre´viamente sugeridas como comprometidas na doenc¸a, pelo
que pode constituir um ponto de charneira na regulac¸a˜o glutamate´rgica.
Finalmente, a medic¸a˜o dos nı´veis se´ricos de hormonas tiroideias num
estudo piloto indica existirem nı´veis diminuı´dos de triiodotironina livre nos
doentes do sexo masculino, quando comparados com indivı´duos sauda´veis.
A possibilidade desta alterac¸a˜o estar relacionada com a manifestac¸a˜o da
doenc¸a necessita ainda de ser investigada.
Em conjunto, os nossos resultados apoiam a hipo´tese do envolvimento
das hormonas tiroideias na esquizofrenia e abrem perspectivas para a per-
tineˆncia de estudos detalhados ao nı´vel da expressa˜o de genes.
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General introduction
2 General introduction 1
Schizophrenia is a severe and disabling mental illness. It is characterized
by disturbances in brain function, leading to a maladjustment to reality. Pa-
tients present a wide range of symptoms and signs indicative of alteration in
cognitive, emotional, motivational, perceptual, and motor functions [210]. So
far, no cure exists, which makes schizophrenia a chronic disorder. The cur-
rently available medication is not effective in all patients, and often provides
only partial alleviation of disease symptoms at the cost of significant side ef-
fects for many patients [112].
Both genetic and environmental risk factors are believed to participate in
the etiology of the disease. Establishing the genetic causes underlying schizo-
phrenia would offer the opportunity not only for using a molecular diagnosis but
also for the development of more effective treatments. The work presented in
this thesis contributes to the progress in schizophrenia research by investi-
gating whether two classes of modulators of gene expression, namely thyroid
hormones and retinoids, are involved in the etiology of this disorder.
To introduce the reader to the main body of the material presented in Chap-
ters 3 through 7, we first embark on a review of the schizophrenia disorder,
including its prevalence, its diagnosis and known facts about its physiological,
genetic, and environmental background (Section 1.1). Nowadays, the view
that schizophrenia is a neurodevelopmental disorder is commonly accepted.
We will discuss this view (Section 1.1.7) and how the thyroid hormone and
retinoid hypotheses fit in it (Section 1.2). Finally, we will describe the types
of approaches most commonly pursued in the molecular study of the genetic
basis of schizophrenia (Section 1.3).
1.1 Schizophrenia
Schizophrenia is a heterogeneous disorder identified on the basis of a pat-
tern of abnormal behavior, characterized by false beliefs and abnormal per-
ceptions. The symptoms presented by schizophrenic patients can be divided
into two main types. The “positive symptoms” refer to normal functions that
are distorted or exaggerated. These include hallucinations or abnormalities
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in perception; delusions or abnormalities in inferential thinking; disorganized
speech or abnormalities in language; disorganized behavior or abnormalities
in behavioral monitoring and control. The “negative symptoms” are those that
represent diminution or loss of normal mental functions. These include alogia
or a decrease in the fluency of ideas and language with consequent difficulty
in maintaining a continuous conversation; affective blunting or difficulty in ex-
pressing emotions; avolition or extreme apathy with lack of initiative, drive, and
energy to pursue goal-directed activities; anhedonia or lack of pleasure and
interest in life; attention impairment or a decrease in the ability to focus at-
tention (reviewed in [13]). Note that none of these symptoms are specific to
schizophrenia, nor present in all patients.
In many schizophrenic patients cognitive impairments are also observed.
Patients with schizophrenia generally perform poorly on psychological tests
of attention, memory, executive functions, and information processing. Inter-
estingly, these impairments are also observed in individuals with high risk of
developing schizophrenia, and have been proposed as predictive or as early
signs of the illness [96]. Although more severe in patients, cognitive deficits
are also present in their unaffected siblings [48], which suggests that cognitive
deficits are heritable. It has been noted that these cognitive deficits are usually
nonprogressive and relatively stable over time [123, 143].
It has been proposed that patients with predominantly positive symptoms
more often have acute onset, good prognosis, and favorable response to medi-
cation. In contrast, patients with predominantly negative symptoms more often
present a chronic course, poor prognosis, inadequate response to medication,
and evidence of cognitive impairment [37].
1.1.1 Prevalence
Although the clinical course of schizophrenia varies considerably between
populations, the median lifetime prevalence of 0.7-0.8% [324] shows surpris-
ingly little variation across populations that vary widely in climatic and social
environment, and that have been genetically separated for many thousands
of years [171]. This fact has been interpreted as a result of a schizophrenia
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genesis early during the evolution of modern Homo sapiens combined with
a possible evolutionary advantage associated with the trait [30]. This could
explain the persistence of schizophrenia despite the decrease in procreation
observed in patients [126].
Typically, the age of onset of schizophrenia ranges from mid- to late ado-
lescence through early adulthood, and usually it manifests itself 3 to 5 years
earlier in males [171, 98]. It is widely accepted that in younger age groups,
the risk of developing schizophrenia is higher for males while beyond age 40
the risk is higher for females [10]. In addition, a higher incidence of schizo-
phrenia in males has been reported in developed countries [10]. However, the
existence of sex differences in life time morbid risk is not consensual. In fact, it
has been proposed that the reported gender difference regarding prevalence
could arise from higher severity of the illness in males, which would make it
easier to recognize [208].
In any case, symptomatic sex differences have become obvious in recent
studies. Male sex is associated to an earlier onset and a more severe course
of the illness, with a higher proportion of male patients being refractory to the
treatment and with aggression and violent behaviors being also more common
in males. Males also show more negative symptoms and cognitive deficits. Fe-
male patients present more affective symptoms, auditory hallucinations, and
delusions, with faster and greater response to medication but with increased
level of side effects [208]. Whether brain pharmacological effects of repro-
ductive hormones are associated with sex differences found in patients is still
unclear. However, the existence of a link between the later age of schizo-
phrenia onset among woman and their higher estrogen secretion has been
hypothesized [305]. Higher cognitive abilities have been reported in female
patients with higher levels of estrogen [150]. Confirming this observation, it
was shown that women to whom estrogen has been administered present a
better clinical response to treatment [192]. In addition, lower estrogen levels
were reported in psychotic patients in comparison to healthy subjects [158].
Several models have been proposed to explain the observed symptomatic
differences between male and female schizophrenic patients, but to date none
is regarded as conclusive [208].
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1.1.2 Diagnostic methods
The clinical definition of schizophrenia is particularly difficult because of in-
terindividual variation, with the diagnostic decision being made by drawing an
artificial line in a continuous behavior scale ranging from normal to schizo-
phrenic [126]. The diagnosis of schizophrenia is mostly done in accordance
with two standardized classification systems that have been extensively tested
and revised to improve their reliability and validity: the Diagnostic and Statis-
tical Manual for mental disorders, currently in its fourth edition (DSM-IV) [12];
and the International Classification of Diseases, now in its tenth edition (ICD-
10) [410]. The two classification systems take a purely descriptive approach
and define schizophrenia on the basis of presenting clinical signs and symp-
toms. The systems do agree and essentially differ only in terminology [126].
These are comprehensive and time-consuming diagnostic tools. An alterna-
tive is the Operational Checklist for Psychotic Disorders (OPCRIT), a classifi-
cation system for mental illnesses which provides a convenient, reliable, rapid,
and valid approach to diagnostic assessment [237, 21].
The Diagnostic Interview for Genetic Studies (DIGS) is a commonly used
semi-structured interview that combines information from many different diag-
nostic tools, including those mentioned above [283]. The purpose of the DIGS
is to provide researchers in psychiatric genetics with the broadest possible
dataset and to ensure maximum compatibility with datasets obtained through
other instruments. These features of DIGS make it particularly valuable for the
precise and reliable definition of populations for genetic studies. The DIGS
provides a rich collection of details about the phenomenology of schizophre-
nia and mood disorders, more so than many other diagnostic instruments.
It brings together not only items found in several other systems but also in-
cludes further items regarding mixed states of mania and depression, rapid
cycling, suicidality, co-morbidity, and course of illness. Furthermore, the DIGS
provides comprehensive assessment of substance consumption, abuse, and
dependence, which is of prime importance to prevent false positives. Such
extensive phenomenologic detail may allow the construction of quantitative
phenotypes or the definition of new biologically based categories [283].
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The original DIGS, which uses the English language, has been translated
to various other languages, including Portuguese [20]. The Portuguese ver-
sion has been used to assess individuals in the Portuguese and Brazilian sam-
ples used in our studies. The translation to Portuguese has been meticulously
performed to preclude distortions, also on the conceptual level. An indepen-
dent reverse translation has been compared with the original to verify close
correspondence.
The reliability of the DIGS has been assessed through various test-retest
and inter-rater experiments, and has been found to be high or excellent for the
schizophrenia disorder [283, 299]. The inter-rater reliability of the Portuguese
version was also studied, and found to be excellent [20].
As mentioned above, schizophrenia does not constitute a homogeneous
phenotype. Its standard diagnosis may include a variety of overlapping con-
ditions with different symptoms, courses, outcomes, responses to treatment,
and etiologies. In fact, given the complexity of brain functions, classification of
schizophrenia based on observed behavior might not be optimal for the genetic
dissection of the disease. One increasingly popular strategy is trying to under-
stand the genetics of schizophrenia by understanding the genetics and gene
linkage of specific trait markers, known as endophenotypes. Endophenotypes
include neurophysiological, biochemical, endocrinological, neuroanatomical,
and cognitive measurements more consistently associated with a genetic trait
than the clinical symptoms. Such traits should by definition be heritable, more
common in affected individuals than in the general population, and also ex-
pressed at higher rate in unaffected biological relatives, marking them as car-
riers of the predisposing alleles [106]. For schizophrenia, some success has
been achieved in establishing linkage between specific chromosomal loci and
specific endophenotypes.
A substantial body of evidence indicates that schizophrenia patients present
ocular motor abnormalities. In particular, the normal smooth pursuit of a mov-
ing target with the eyes is fragmented, resulting in abrupt, darting eye move-
ments (saccade). Such eye-tracking abnormalities are present both in patients
suffering from schizophrenia (50 to 80%) and in their first-degree relatives
(40%) in a higher percentage than in the general population (8%). This ob-
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servation suggests that it could be used as a phenotypic marker for finding
schizophrenia susceptibility genes [152]. A positive linkage to this trait was
reported on chromosome 6p [17].
The P50 auditory evoked response is an information processing paradigm
involving exposure to two paired stimuli. An initial stimulus induces an exci-
tatory reaction in the brain that also activates inhibitory mechanisms, damp-
ening the excitatory response to a subsequent identical stimulus. Inhibition of
the P50 response to the second stimulus is present in 90% of the general pop-
ulation, but in only 50% of schizophrenic patients [107]. Family members of
schizophrenic patients also present decreased P50 inhibition which suggests
that it could function as trait marker, and its use in linkage analyses may facil-
itate the identification of genetic liability to schizophrenia [6]. In fact, positive
linkage to this trait was reported on chromosome 15q14 [107].
Other trait markers have also been suggested as endophenotypes [127].
In particular, brain imaging studies may reveal novel anatomical and functional
disease-specific features relevant for the diagnosis of schizophrenia.
1.1.3 Affected brain structures
Several neuroimaging techniques, like computed tomography (CT) and mag-
netic resonance imaging (MRI), along with conventional postmortem studies,
have been used to examine the anatomical changes present in the brains of
schizophrenic patients.
Early histopathological approaches to identifying postmortem abnormal-
ities in brains of schizophrenic patients were too crude to consistently de-
tect the small and subtle abnormalities believed to be involved in schizo-
phrenia. Nevertheless, they established the absence of massive cell loss or
glyosis [141]. More recent histopathological examinations have reported an
increase in cell-packing density without a change in neuronal number, indicat-
ing a decrease in neuropil density and a reduction in dendritic spine density in
the pyramidal neurons of the prefrontal cortex [118, 336].
The development of neuroimaging techniques, first CT in the late 1970s
and shortly after MRI, produced a revolution in the field since it enabled the
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evaluation of brain structural alterations without the limitations of postmortem
brain studies. Although both techniques allow detection of neuromorpholog-
ical alterations as well as assessment of cerebral volumes, MRI became the
standard tool for assessing changes in brain structure since it provides greater
spatial resolution and high contrast resolution for neuroanatomical structures
and grey-white matter distinction than the CT technique. In addition, MRI al-
lows greater flexibility for adapting acquisition parameters to the particular tis-
sues and regions under study. MRI has yet another advantage over CT. While
CT involves exposure to ionizing radiation, during an MRI procedure the pa-
tient is only submitted to a magnetic field, to which no known biological risks
are associated.
Structural analysis revealed that ventricular enlargement is the most con-
sistently found anatomical alteration in schizophrenic brains. Over 75% of CT
studies and 80% of the MRI studies in schizophrenia revealed enlarged lateral
ventricles [340]. However, it should be noted that such alteration is not spe-
cific to the schizophrenia pathology and can also be found in other disorders,
including Alzheimer’s disease and hydrocephalus [8].
Some MRI studies also show a reduction in whole-brain volume, but this
reduction is relatively small [392]. If we assume that these subtle whole-brain
differences do not reflect uniform affection of all neuroanatomical regions, we
may expect that examination of specific areas might show more substantial rel-
ative decreases in volume. Volumetric MRI scans have detected regional brain
changes with specific gray matter volume reduction particularly in the superior
temporal gyrus and in medial temporal structures, such as the amygdala and
the hippocampus [202, 340].
Valuable information stems from studies of monozygotic (MZ) twins discor-
dant for schizophrenia. An MRI study of discordant MZ twins indicated that the
schizophrenic twin can be characterized by brain ventricular enlargement, and
reduction of hippocampus and temporal lobe when compared with the non-
schizophrenic twin [355]. This, together with the observation that unaffected
relatives have smaller ventricles than schizophrenic patients, but larger than
control subjects from families without schizophrenia [203, 339], supports that
ventricular enlargement is associated with the disease and that it is caused by
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the effect of environmental factors in genetically susceptible individuals. Addi-
tionally, a longitudinal study of adolescents at high risk of developing schizo-
phrenia showed that brain ventricular enlargement correlated positively with
genetic risk of schizophrenia in adulthood [182].
In summary, histopathological and neuroimaging studies demonstrate sub-
tle structural brain changes that provide clues regarding the pathophysiology
of schizophrenia.
1.1.4 Pharmacological aspects
The first attempts to understand the biochemical basis underlying schizophre-
nia were based on the mechanisms of action of the drugs capable of alleviating
disease symptoms. These drugs, known as antipsychotics or neuroleptics, are
usually divided in two classes: typical and atypical.
Typical neuroleptics were introduced in the early 1950s. Some of the
typical neuroleptics frequently used are: haloperidol (Ortho-McNeil Pharma-
ceutical, Raritan, NJ, USA), chlorpromazine (Smith, Kline and French, Ltd.,
Philadelphia, PA, USA), promazine (Wyeth Pharmaceuticals, Philadelphia, PA,
USA), and thioridazine (Sandoz Pharmaceuticals, East Hanover, NJ, USA).
Based on the mechanism of action of these drugs, schizophrenia was at-
tributed to hyperactivity of dopaminergic transmission [84]. The antipsychotic
action of these first generation drugs correlates with their ability to block do-
pamine receptors, particularly the D2 subtype of dopamine receptors [335].
Morover, dopamine agonists like amphetamines and cocaine, which act by
promoting the release of dopamine, can induce psychosis in healthy individ-
uals as well as aggravate schizophrenic symptoms in patients [51]. Direct
validation of dopamine dysregulation in schizophrenia has come from brain
imaging studies in schizophrenic patients, which showed higher release of do-
pamine at the synaptic junction in response to amphetamine stimulation than
in non-schizophrenic controls [4, 38].
With time, it became apparent that these classical drugs are not effec-
tive in the treatment of all patients and, when effective, mainly reduce posi-
tive symptoms [206]. Furthermore, they frequently induce neurological side
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effects. While the antipsychotic effects probably result from blockage of dopa-
mine receptors in limbic areas, such as the nucleus accumbens and prefrontal
cortex of the brain, the Parkinsonean side-effects provoked by these neurolep-
tics is caused by D2 receptor blockage in the caudate putamen region [206].
Doubts about the requirement of direct blockage of D2 receptors for an-
tipsychotic drug effectiveness, were raised by the introduction of atypical neu-
roleptics. These include clozapine (Novartis, Switzerland), olanzapine (Lilly,
Indiana, USA), quetiapine (Astra-Zeneca, Sweden) and risperidone (Janssen,
Belgium). These neuroleptics were found to be more effective than classical
drugs. They do not only reduce positive but also negative symptoms, display a
lower incidence of side effects, and clozapine in particular can cause substan-
tial improvement in patients who fail to respond to other neuroleptics [43, 206].
Besides influencing the dopaminergic pathway, these novel drugs also have
affinity for other types of neurotransmitter receptors, such as those for sero-
tonin and glutamate.
Serotonin may play a role in the schizophrenia pathophysiology. Support-
ing this hypothesis is the observation that atypical drugs present greater po-
tency then typical ones to block 5-HT2 subtype of serotonin receptor [241],
and that structural similarities exist between serotonin and LSD (lysergic acid
diethylamide), a potent hallucinogen. It has been shown that serotonin recep-
tors and its uptake sites are altered in the limbic system of individuals suffering
from schizophrenia [174].
The glutamatergic system has also received considerable attention. In par-
ticular, a hypofunction of N-methyl-D-aspartate (NMDA) glutamate receptor
has been proposed [368]. This hypothesis has arisen from the observation
that NMDA receptor antagonists, such as phencyclidine (PCP), ketamine, and
MK-801, mimic schizophrenia in healthy individuals even more faithfully than
amphetamine, since their administration results not only in positive symp-
toms but also in negative symptoms and cognitive impairments [361]. Fur-
thermore, they are capable of exacerbating symptoms in schizophrenic pa-
tients [193, 206]. These NMDA antagonists act by blocking the binding of glu-
tamate to the NMDA receptor. Notably, treatment with clozapine, but not with
the typical neuroleptic halopiredol, attenuates clinical symptoms produced by
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ketamine [222], possibly by increasing the expression of NMDA-receptor which
facilitates glutamatergic transmission [121]. Additionally, transgenic mice with
reduced expression of NMDA receptor subunit 1 (NR1) or lacking the NMDA
receptor ε1 subunit orthologous to the human NMDA receptor subunit 2A
(NR2A) exhibit the same behavioral abnormalities as induced by NMDA antag-
onists in animal models of schizophrenia [259, 256]. Interestingly, kynurenic
acid, an endogenous antagonist of NMDA receptors, has been reported to be
increased in the hippocampus in postmortem studies of schizophrenics [334].
Unlike other neurotransmitter receptors, the NMDA receptor requires ac-
tivation by two types of molecules. Besides the glutamate recognition site,
the NMDA receptor also presents a distinct site for binding glycine or the D-
isomer of serine depending on the brain area [272]. The glutamate hypothesis
of schizophrenia has found strong support in studies establishing that agents
acting at the glycine modulator site of the NMDA receptor cause symptomatic
improvements in patients [147, 369]. Note that administration of direct agonists
at the NMDA receptor has not been tried because of the risk that excessive
glutamate stimulation may cause excitotoxic damage to neurons [201].
It is important to point out that the three alternative hypotheses presented
above are not necessarily mutually exclusive since the various neurotransmis-
sion systems are known to interact [284]. In fact, recent theories suggest that
glutamate receptors play a central role in the aberrant neurological processing
found in schizophrenic patients [257], and that dopaminergic and serotonergic
changes may be secondary to the altered glutamatergic transmission [7, 198].
Although these theories attempt to describe the occurring dysfunction, they
provide no explanation of the etiological events underlying schizophrenia.
1.1.5 Genetic epidemiology
The classical genetic epidemiological approach of family, adoptee, and twin
studies has been remarkably consistent in establishing a significant role for
genetic inheritance in the etiology of schizophrenia [238].
Evidence from family studies clearly demonstrates that schizophrenia ag-
gregates in families, and that the risk of developing schizophrenia is directly
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Figure 1.1: Each bar represents the risk to develop schizophrenia, in percentage. The
degree of genetic relationship to the affected individual is represented by the bar pattern. The
data are based on the review of studies collected by Gottesman [126].
linked to the degree of genetic relationship to an affected individual [262]. Fig-
ure 1.1 summarizes the evidence. Children and siblings of individuals with
schizophrenia present a risk of developing the disorder that is roughly 10 times
higher than the normal population. For second and third degree relatives, the
risk is also increased, in smaller, but consistent degree. Moreover, the risk
increases with the number of affected relatives. For example, the risk is 13%
if only one parent is ill, and 46% if both parents are affected. Schizophrenia
often coexists in families with other psychotic disorders [181].
Adoption studies indicate that children of individuals with schizophrenia,
when adopted, still present a higher risk of developing schizophrenia, as ex-
pected for first-degree relatives [167, 363]. In biological relatives of schizo-
phrenic adoptees, disease incidence is higher, and in the adoptive families
of both affected and control adoptees, schizophrenia rates are low and simi-
lar [183]. Thus, the increased risk found in families is related to genetic factors
and cannot be explained by family environment or by the stress of living with
affected individuals.
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Twin studies have provided the most significant evidence for the presence
of a genetic component. The methodology of twin studies is based on the
observation that while monozygotic (MZ) twins have identical genotype, dizy-
gotic (DZ) twins share, on average, 50 percent of their genes. Therefore, if
genes play a major role in disease susceptibility, the concordance rates (ex-
tent to which both members of a twin express the trait) would be considerably
higher in MZ than in DZ twins. In fact, it has been consistently shown that
schizophrenia concordance rates in MZ twins are approximately 50%, which is
higher than the 17% concordance rates found in DZ twins [50], providing con-
clusive evidence of a genetic effect. The similar risk present in the offspring of
discordant MZ twins [126] provides evidence that the cause of discordance in
MZ twins is due to environmental and/or epigenetic factors.
The patterns of schizophrenia risk, observed in family and twin studies,
provide clues regarding the mode of transmission of the disease. The fact that
the risk for schizophrenia is higher in close relatives of affected individuals, but
decreases rapidly in more distant relatives, implies that a single-locus trans-
mission model of the disease must be rejected [290]. In fact, the involvement
of multiple genes is supported by linkage studies that have identified several
chromosomal regions as potentially containing risk genes (see Section 1.3).
A possible explanation of the observed risk patterns is provided by a poly-
genic multifactorial model of transmission, with a threshold effect for disease
manifestation [126]. This model assumes a complex etiology involving multiple
genes and environmental factors. The effects of each factor combine additively
(total liability from several factors is the sum of liabilities of each factor sepa-
rately), and the trait manifests itself when liability exceeds a certain threshold.
Thus, although the schizophrenia diagnosis is dichotomous (present or ab-
sent), liability to the disorder is a quantitative measure, normally distributed
over the general population. In contrast to a single-gene disorder, in a poly-
genic disease, possession of a particular susceptibility gene does not mean
that an individual will necessarily develop the disease, but just that he/she is at
increased risk; in fact, the majority of carriers are not expected to express any
clinical phenotype [214]. Only individuals who are above a certain threshold
of liability due to a combination of risk factors, will develop the disease. The
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incidence of the disorder is greatest among relatives of affected individuals be-
cause they are more likely to aggregate several of these risk factors and thus
on average have a bigger chance to be above the threshold, i.e. they have a
higher liability to develop the disorder than the general population.
Apart from the polygenic multifactorial threshold model, the observed pat-
terns of risk of schizophrenia are also compatible with a model of multiple loci
with epistatic interaction. In such an epistatic model, the rapid increase of risk
with degree of genetic relatedness is explained by non-additive combination of
gene effects, where interactions between genes confer a total liability greater
than the sum of their individual effects [311].
In conclusion, in the majority of cases, schizophrenia probably results from
a combination of many risk genes, each of small effect, which, as the MZ twin
discordance rate of 52% imply, must be substantially modulated by environ-
mental factors.
1.1.6 Environment
Epidemiological studies have identified a number of environmental factors,
such as maternal malnutrition, prenatal infections, and obstetric complica-
tions, associated with increased rates of schizophrenia in at least some pa-
tient groups [47, 160]. These early events can explain a significant portion
of the variance, although they do not have as much predictive power as the
genetic factors. In fact, most of the individuals that experience these sorts of
adverse environmental events do not develop schizophrenia [154]. Most likely,
they need to be combined with additional susceptibility factors to lead to ill-
ness. The environmental stressors implicated can be subdivided according to
the time in which they exert their effect: in the prenatal period, the perinatal
period, or during childhood and early adolescence.
Prenatal period
Two independent studies have reported an association between prenatal ex-
posure to severe malnutrition and the offspring’s risk for schizophrenia in adult-
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hood, especially if the exposure is in the first trimester of gestation [350, 358].
Although the Dutch hunger winter of 1944-1945 and the Chinese famine of
1959-1961 represent different circumstances of famine, culture, and ethnicity,
the findings are remarkably consistent, with the two studies reporting a twofold
increase in risk for schizophrenia in both male and female offspring prenatally
exposed to famine. Interestingly, it seems that the early pregnancy exposure
to famine only increases the risk for schizophrenia and not for other psychiatric
disorders [358].
A series of studies on influenza epidemics have reported, though not con-
sistently, an increased risk of developing schizophrenia in the offspring ex-
posed during gestation, with some studies indicating that the increase is es-
pecially noticeable when the infection occurs during the second trimester of
gestation [236]. Even when considering positive results, the observation is
that influenza can account for only a small minority of cases. More recently,
elevated serum cytokine levels in mothers prior to delivery of individuals who
later develop schizophrenia have again implicated influenza, rubella, and res-
piratory infections in the schizophrenia etiology [41, 42, 45]. In addition, re-
cent reports provide further indications for a role of the immune system in the
schizophrenia etiology [245, 243]. However, it should be noted that influenza
exposure in utero has been reported to also increase the risk to other psychi-
atric disorders [219, 244, 14].
Experimental studies in animals have provided support for the influence
of viral infection in schizophrenia risk. Infection of pregnant mice with human
influenza virus results in offspring that display several “schizophrenia-like” be-
haviors [341]. Moreover, similar behavioral changes were detected in the off-
spring of mice who where submitted, during pregnancy, to immune challenges
that mimic a viral infection [341]. This provides evidence for the influence of
the immune response on brain development.
Perinatal period
Obstetric complications, during pregnancy or at the time of delivery, are re-
ported to be more frequently observed in persons who later develop schizo-
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phrenia. A meta-analysis reported that people exposed to obstetric compli-
cations have twice the risk to develop schizophrenia with respect to people
that did not suffer from obstetric complications [113]. In a large, more recent
study, the increased risk for schizophrenia was observed for several obstetric
complications, such as preeclampsia, low birth weight, and severe prematurity
(gestational age below 33 weeks) [68]. In this study preeclampsia seems to
be the stronger risk factor with an increase of risk between 2 to 2.5 times. In-
terestingly, preeclampsia, which occurs during the third trimester of pregnancy
and is characterized by edema, high blood pressure, and the presence of pro-
tein in the urine, is associated with a reduction in fetal nutrition [225]. Also, low
birth weight, when corrected for gestational age, can be considered a sign of
malnutrition. Therefore, the precise factors that relate obstetric complications
with schizophrenia, if confirmed, still need to be identified.
Although obstetric complications were consistently associated with schizo-
phrenia their overall effect is small. That is, the presence of obstetric com-
plications has a low predictive value for schizophrenia manifestation and their
presence is not sufficient for the illness to appear. Studies of the effect of
obstetric complications on brain development of patients, their unaffected rela-
tives, and controls, have provided evidence for the interaction between genetic
and environmental factors during neurodevelopment [234, 333]. These stud-
ies have shown that obstetric complications have a restricted effect in brain
development of control subjects, while in patients they induce a decrease in
left hippocampal volume and an increase in lateral ventricular volume. The
same alterations found in schizophrenics were also observed in non-affected
relatives, though less pronounced. This suggests that obstetric complications
may have a greater effect in brain development of individuals that have a ge-
netic susceptibility to schizophrenia compared to those that do not have this
predisposition. Finally, note that obstetric complications appear to increase
the risk not only for schizophrenia, but also for affective disorder [223].
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Childhood and early adolescence
Other environmental risk factors seem to have a more postnatal influence,
such as growing up in an urban area, migration or minority status, and the use
of drugs, in particular of cannabis.
Recent studies have shown that individuals that grow up in an urban en-
vironment present an increased risk of schizophrenia when compared with
those growing up in rural areas [287]. However, it is not clear whether this as-
sociation actually reflects a higher exposure to other factors, such as infection,
toxins, or malnutrition, which may be more common in urban populations.
It has been reported that migrants present a higher incidence of schizo-
phrenia, possibly due to chronic exposure to discrimination [163]. In a recent
review, the relative risk for developing schizophrenia was indicated to range
from 2.7 in first-generation migrants to 4.4 in second-generation migrants [49].
These observations are supported by social isolation studies in animals,
which show association between temporal loss of maternal care in critical
early periods of rodent development and changes in the dopamine system
characterized by enhanced dopamine release after amphetamine administra-
tion [135]. These molecular changes induce long lasting alterations in be-
havior, similar to those found in schizophrenia [92, 162]. In contrast, when
similar studies are conducted in post-weaning rats (isolation rearing) the be-
havior impairment is not permanent [377] and can be prevented if for instance
the isolation-reared mice are handled [190]. Altogether, these studies suggest
that stress is more disruptive in early stages of brain development. Interest-
ingly, the behavioral alterations only become manifest after “puberty” in rats,
and persist thereafter, though both typical and atypical antipsychotics can re-
store the normal behavior [92]. Additionally, the fact that not all rat strains
display behavior alteration when submitted to social isolation, emphasizes
the role of genetic background in the effects of pre- and neo-natal manipu-
lations [398, 91]. Note that social isolation during postnatal development has
been reported to predispose also to depression and anxiety behaviors in adult-
hood [144, 399, 131].
The use of psychoactive drugs, in particular cannabis, during adolescence
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was found to be associated with an increased risk of psychosis in adulthood [18,
136]. Interestingly, a recent study revealed that individuals with schizophrenic
affected relatives were more likely to develop prolonged psychosis after the
drug use than subjects who had no family history of schizophrenia [146]. This
suggests that the use of dopamine-releasing drugs is acting as a trigger in
individuals that are particularly sensitive to dopamine, which by exceeding the
threshold results in psychosis.
The influence of these childhood and early adolescence factors seems
to fit in the so-called “vulnerability-stress” model of the schizophrenia etiol-
ogy [421, 381]. This model suggests that predisposed individuals will manifest
the disease particularly under conditions of stress which may be either psy-
chosocial or physical. This model does not exclude the presence of strong ge-
netic predisposition in which the illness would be manifest even without these
stressors.
The main idea that schizophrenia has its etiology in gene-environment in-
teractions acting during brain development does not specify any particular
gene, or environmental factor that can be responsible for the neurodevelop-
mental impairment. However, data from a variety of sources support that, inde-
pendently of the specific genetic and environmental causative agents, schizo-
phrenia is a disease with genesis in brain development [304].
1.1.7 Abnormal neurodevelopment
The view of schizophrenia as a neurodevelopmental disorder is based on ob-
servations suggesting that the abnormalities found in schizophrenia have an
early onset in the life of individuals who later develop the disorder. The neu-
rodevelopmental theory of schizophrenia is based on robust evidence derived
from diverse sources (for a review see [225]), and proposes that genetic sus-
ceptibility combined with environmental perturbations during critical periods of
neural development lead to abnormal neurodevelopmental trajectories. Views
differ in the timings and nature of the disturbance(s). Still, based on predic-
tions that many environmental events associated with an increased risk for
schizophrenia occur during prenatal and perinatal periods of life, it is likely that
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Figure 1.2: According to the neurodevelopmental hypothesis of schizophrenia, genetic fac-
tors combine with environmental events during early periods in life to produce neurodevel-
opmental abnormalities that predispose to schizophrenia. The specific way in which these
factors interplay remains to be elucidated. Additional environmental insults later in life, such
as during adolescence, may cause neurodevelopmentally impaired individuals to actually de-
velop schizophrenia.
brain development begins to deviate already in utero and is probably affected
by events around birth, and that environmental stressors such as drugs and an
adverse social environment around adolescence may drive neurodevelopmen-
tally impaired individuals over some threshold, inducing the clinical phenotype
recognized as schizophrenia [154] (Figure 1.2).
Neuroimaging studies have confirmed that schizophrenia is associated
with brain structural abnormalities (see Section 1.1.3). The size reduction in
some structures found in brains of schizophrenic patients could have neurode-
velopmental or neurodegenerative causation or could result from a combina-
tion of the two. The proliferation of glia, the most numerous type of brain
cells, to form a glial scar (termed gliosis) has been considered the hallmark
of neurodegenerative processes involving cell loss that is not apoptotic. The
absence of gliosis in postmortem schizophrenic brains has been interpreted
as evidence that the disease is not degenerative in the classical sense and
should thus be developmental [397].
Knowing the time when brain changes occur is essential for understand-
ing their significance in the etiology of schizophrenia. A neurodevelopmental
model of schizophrenia is supported by the observations that ventricular en-
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largement, reduced hippocampal volume, decreased pyramidal cell volume,
and lower glial cell density in the medial temporal lobe and hippocampus, are
already present at disease onset in first-episode patients [396, 294], which
excludes the possibility that they are consequences of medication or disease
pathophysiology. Moreover, these alterations have also been reported in un-
affected young individuals who have a high genetic risk of developing schizo-
phrenia due to their family history [203], supporting the idea that the brain
changes precede the disease onset.
A developmental abnormality in schizophrenia is also supported by retro-
spective clinical observations that pre-schizophrenic individuals often exhibit
minor deviations in motor, cognitive, and social development during childhood
and adolescence [96, 289]. In addition, an increased frequency of minor phys-
ical anomalies such as curved fingers, low-set ears, and high-arched palate,
have been detected in schizophrenic individuals [240]. Such slight deviations
in external physical characteristics are indicators of problems of fetal develop-
ment [235]. Additionally, several genes implicated in the schizophrenia etiology
(see Section 1.3) can be linked with neurodevelopment such as: retinoic acid
receptor alpha (RARα) [309], myelin-basic protein [134], G-protein signaling-4
(RGS4) [411], calcineurin [129], and neuregulin [330].
Brain development is a highly complex biological process. It certainty re-
quires the contribution of several genes and non-genetic factors in a tightly
controlled program of events. When a specific factor eliminates, alters or post-
pones a specific development step it is possible that the normal development
of the brain is compromised and that it will predispose for later psychiatric
problems. However, while it is easy to accept that an abnormal neurodevelop-
ment could cause childhood disorders like autism, it is harder to understand
how it can be involved in the schizophrenia etiology in which the behavioral
sequels of these early events remain almost completely dormant until after
puberty. Nevertheless, we should keep in mind that human brain development
is an ongoing process that continues into early adulthood, when maturation of
some central circuits probably leads to the emergence of disease symptoms.
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1.2 Retinoids and thyroid hormones
The hypothesis of abnormal neurodevelopment caused by gene-environment
interactions acting during brain development provides a framework of thought
and experiment, but is not testable as such, since it does not specify any
particular gene, environmental factor, or pathway that might be involved. In
the sequel, we will explain how the hypothesis can be made more concrete
and testable.
Gene-environment interactions occurring during brain development estab-
lish the way in which nerve cells are laid down, differentiated, selectively culled
by apoptosis and remodelled by expansion and retraction of dendrites and
synaptic connections. The complex range of schizophrenic symptoms and out-
comes could be produced by the multitude of time points at which the normal
brain development can be affected. Several gene-environment interactions
could be responsible for alterations in neurodevelopment. Inadequate nutri-
tional or hormonal signaling, which disrupts proper gene transcription, could
justify the heterogeneity of clinical presentations and the multiple cellular sys-
tems affected, depending on the moment during brain development at which
the abnormality takes place.
Proper nutrition is crucial to the correct structural and functional develop-
ment of the central nervous system (CNS). Severe maternal nutritional defi-
ciency has been related to increased offspring’s risk for developing schizo-
phrenia later in life, as explained previously (Section 1.1.6). Nevertheless, it
is not known whether the increased predisposition arises from a global nutri-
tional deficiency or from a specific micronutrient deficiency. Reduced supply
of nutrients, such as oxygen, iron, glucose, vitamin A, and iodine to the fe-
tus may lead to impaired CNS development and consequently influence the
risk to develop schizophrenia. Several hypotheses have been formulated in
order to serve as mechanistic models of how micronutrients could contribute
to schizophrenia genesis.
Below, we will formulate a hypothesis for the schizophrenia etiology based
on abnormalities in retinoid and thyroid hormone metabolism.
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1.2.1 Influence of retinoids on brain function and behavior
It has been proposed that dysregulation of retinoid signaling may play an im-
portant role in the etiology of schizophrenia [194, 125]. Several lines of evi-
dence support this hypothesis.
First, retinoids (vitamin A, or retinol, and its metabolites) regulate cellular
proliferation, differentiation, and apoptosis [348]. A proper regulation of these
processes is required for a correct formation of the body axis and for the nor-
mal development of several organs, including the brain [269]. It has been
reported that when retinoic acid (RA) concentrations deviate from normal val-
ues during embryonic development, in either direction, abnormal development
occurs [221, 151].
Second, excess or deficiency of retinoids during development can produce
several signs of schizophrenia, including thought disorder, mental deficit, en-
larged ventricles, and minor physical anomalies [125]. Moreover, the fact that
these retinoid-related anomalies are often also observed in relatives of schizo-
phrenic patients, suggests that genetic susceptibility to alterations in retinoid
metabolism may be present in schizophrenic families [124].
Third, many genes regulated by retinoids or involved in their metabolism
are localised in chromosomal regions which have been implicated in schizo-
phrenia by linkage studies [125].
1.2.2 Retinoid metabolism
Vitamin A is an essential nutrient. It can not be synthesised by the human
body, and needs to be acquired through diet. During gestation, the maternal
diet must make vitamin A available to the developing fetus, via blood supply.
Figure 1.3 presents a schematic overview of the retinoid metabolism. The
main sources of vitamin A are provitamin A carotenoids in fruits and vegeta-
bles and retinyl esters from food of animal origin [140]. A crucial role in the
maintenance of vitamin A homeostasis is performed by the liver that works as
a reservoir of retinol, which is drawn from in times of depletion [275]. Retinol
is released into circulation by the liver, bound to retinol-binding protein (RBP).
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Figure 1.3: Schematic representation of the retinoid metabolism. Retinol (ROH) in the
plasma is released from its carrier, retinol-binding protein (RBP) bound to transthyretin (TTR),
and enters the cell where it is bound by cellular retinol binding protein (CRBP). The first step of
synthesis to retinoic acid (RA) is catalyzed by retinol dehydrogenase (RoDH) or alcohol dehy-
drogenase (ADH). The synthesized retinal (RAL) remains bound to CRBP and is then oxidized
irreversibly to RA, which binds to cellular retinoic acid binding protein (CRABP). RA can either
enter the nucleus to bind to its nuclear receptor (RAR or RXR) to activate transcription, or be
inactivated by the enzyme CYP26.
The retinol-RBP complex, in turn, is found bound to transthyretin (TTR) [265].
Within cells, the retinoid concentration seems to be buffered by associ-
ation with soluble proteins: cellular retinol-binding proteins (CRBPs) which
bind retinol in the cytoplasm, and cellular RA-binding proteins (CRABP-I and
CRABP-II) which bind RA [277]. Moreover, these retinoid-binding proteins
may control the metabolism of retinoids by delivering retinoids to various
metabolic enzymes [282, 275]. In particular, CRBP-2 may promote esterifica-
tion by lecithin retinol acyltransferase (LRAT) of retinol to the retinyl ester [115].
CRABP-I has been suggested to promote RA catabolism, whereas CRABP-II
may assist with the transport of RA into the nucleus [78].
RA has been shown to be the active metabolite of retinoids in most biolog-
ical processes [57]. Synthesis of RA occurs via a two-step oxidation of retinol
to RA with retinal as the intermediate product [233].
24 General introduction 1
Several enzymes have been implicated in the metabolization of retinol to
retinal in the first step. Among these are enzymes that belong to the short-
chain dehydrogenase/reductase (SDR; in particular retinol dehydrogenase,
RoDH) and alcohol dehydrogenase (ADH) families [275, 83]. The physiolog-
ical relevance in RA synthesis of ADH-1,-3, and -4 has been demonstrated
by null-mutant mice studies. Adh3- and Adh4-disrupted mice, when subjected
to vitamin A deprivation during gestation, suffer increased post-natal lethal-
ity [77]. Thus, ADH-3 as well as ADH-4 can be considered essential for RA
production under vitamin A deficiency [264]. Additionally, ADH-3 was shown to
be essential for growth under a normal diet [264]. Adh1-disrupted mice have
reduced retinol to RA metabolism, without noticeable alterations [263].
The second step of RA synthesis is catalysed by aldehyde dehydroge-
nases (ALDHs) [83]. Importance of ALDHs in RA synthesis was demonstrated
by disruption of Raldh2 in mice, which results in multiple brain abnormalities
and embryonic lethality soon after RA synthesis should start [278, 246].
RA catabolism, also essential for a proper retinoid metabolism, involves RA
inactivation by cytochrome P450s (CYP26s, in particular CYP26A1, CYP26B1,
and CYP26C1) [5]. Null mutation of CYP26A1 results in abnormal CNS devel-
opment and death soon after birth [5, 325].
The most important mechanism of RA activity involves gene expression
regulation. RA exerts its effect on gene transcription by binding to specific
nuclear receptors that are ligand-activated transcription factors [57, 128]. The
RA signal is transduced by two nuclear receptor families: retinoid X receptors
(RXRα, RXRβ, and RXRγ) are activated by the 9-cis RA isomer, and RA re-
ceptors (RARα, RARβ, and RARγ) by either the 9-cis RA or the all-trans RA
isomer [57]. These receptors indeed mediate the functions of vitamin A during
development, as has been demonstrated by mice lacking functional retinoid
receptors which present multiple developmental defects, including those pre-
viously observed during vitamin A deficiency [406, 215, 242]. Interestingly,
these mice also display behavioral abnormalities, such as spatial learning and
memory deficits [61].
The retinoid nuclear receptors function as RAR-RXR heterodimers which,
when active, bind to RA response elements (RARE) present in the regulatory
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region of multiple genes, modulating their expression. The expression of more
than 532 genes is influenced by RA availability, with RAREs being identified
in around 30 genes [23]. Many of these genes are not the direct targets of
retinoids but are rather modulated by other transcription factors, encoded by
genes whose expression is regulated directly by retinoids [23]. Other types of
indirect regulation have been proposed, including RA’s ability to activate nu-
clear receptor dimers other than RAR-RXR. It has been noticed that RXRs are
general partners for several nuclear receptors other than RARs, including per-
oxisome proliferator-activated receptors (PPAR), vitamin D receptor, orphan
nuclear receptors (namely NR4A2), and thyroid hormone receptors (TR). RXR
seems not to require RA binding to influence co-receptor action, as long as
the appropriate ligand is bound to the co-receptor, but activated RXR may en-
hance action of a heterodimer pair [216] or even activate a partner without
ligand [332].
1.2.3 Influence of thyroid hormones on brain function and
behavior
Thyroid hormones (THs) affect diverse biological processes and are impor-
tant for the functions of various organs through their influence on cellular
metabolism [416]. Although TH affects the function of diverse organs in adults,
the most important effects of TH are probably the ones exerted during growth
and development [189]. This is manifest in the widespread clinical effects of
insufficient supply of TH to the developing brain [268, 19, 189, 58, 72, 120].
Several lines of evidence have shown an association between early alter-
ations of thyroid function and neurodevelopmental disorders [379, 298, 356,
116, 104]. The severity and irreversibility of CNS damage is dependent on the
degree of TH abnormality, the time during development at which it occurs, and
its duration. In particular, serious TH deficiency during pregnancy may result
in spontaneous abortion, stillbirth, and congenital abnormalities [85]. Mater-
nal TH deficiency may also lead to cretinism, a serious form of mental and
physical retardation. More moderate TH deficiency leads to less visible, yet
pervasive, mental impairment that reduces intellectual capacity [346, 189].
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The importance of moment, duration, and magnitude of the TH abnormal-
ity is also borne out by effects of TH administration. Cretinism can result from
maternal TH deficiency that affects the fetus before its own thyroid becomes
functional. The damage is permanent and can not be reversed by post-natal
TH supplementation. On the other hand, cretinism can also be caused by inad-
equate production of TH by the fetus itself, in which case it can be prevented if
TH supplementation is initiated shortly after birth [73]. Mental impairment due
to TH deficiency during gestation can be prevented by maternal administration
of TH before mid-gestation. Organ function abnormalities in adults with hypo-
and hyperthyroidism are reversible to a large degree by TH supplementation
or inhibition of thyroid gland function, respectively.
Because of these intense effects of THs, and because TH exerts its effects
through modulation of the expression of several genes, one can speculate that
abnormal regulation of gene expression in the brain could be a key element
in the explanation of many neurodevelopmental defects, among which schizo-
phrenia [104].
1.2.4 Thyroid hormone metabolism
THs are the only hormones in vertebrates that contain iodine. Iodine is an
essential element which can not be synthesised by the body and needs to
be acquired through diet. Although the necessary amount of daily intake of
iodine is small (ranging from 50-1000 micrograms per day), the scarcity of io-
dine in landlocked areas leads to insufficient dietary supply in many parts of
the globe [385, 218, 390]. Without iodine the biosynthesis of THs is inter-
rupted [53].
Figure 1.4 presents a schematic overview of the TH metabolism. A large
percentage of the ingested iodine is absorbed through the small intestine and
transported to the thyroid gland, where it is concentrated to meet TH require-
ments [53]. The first step in the TH synthesis is the activation of the thy-
roglobulin gene. Thyroglobulin synthesis is up-regulated by thyrotropin, or
thyroid-stimulating hormone (TSH) [86]. After being produced, thyroglobulin
undergoes a series of posttranslational processing steps, including iodine in-
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Figure 1.4: Schematic representation of the thyroid hormone metabolism. TH synthesis
is regulated by the hypothalamus-pituitary-thyroid axis via a feedback mechanism involving
T3 and T4. After secretion by the thyroid gland into circulation, THs are carried by plasma
proteins, such as transthyretin (TTR), thyroxine-binding globulin (TBG), and albumin (ALB).
After release from these carries, TH enters the cell, where the T4 form is deiodinased into
T3 by DIO1 and DIO2. Subsequently, T3 is either inactivated to T2 by DIO3, or it crosses
the nucleus membrane to bind to its nuclear receptor (TR). TR often forms heterodimers with
retinoid X receptors (RXR). The hormone-activated receptor binds to TH response elements
(TREs) to alter rates of gene transcription and consequently levels of mRNA.
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corporation into the tyrosyl residues. Subsequently, a coupling reaction be-
tween pairs of iodinated tyrosine in the thyroglobulin molecules occurs to form
thyroxine (T4), and triiodothyronine (T3) [86]. The posttranslationally modified
thyroglobulin containing TH is stored. When needed, TSH stimulation of the
thyroid gland results in thyroglobulin cleavage leading to the generation of free
THs and the complete degradation of the protein [86]. T4 is the main product
of the thyroid gland. About 10% of T4 is converted within the thyroid gland
to T3 through the action of deiodinases, a family of selenoproteins [367, 188].
Both T3 and T4 are then secreted into the circulation. It is estimated that in
average a person with a normal thyroid function secretes 94-110 µg of T4 and
10-22 µg of T3 daily [102].
THs are insoluble and, once released, are rapidly bound to plasma pro-
teins. In a normal person, less than 0.1% of the total serum T4, and 0.3% of
the serum T3 are present in unbound form [62]. The major serum TH-binding
proteins are thyroxine-binding globulin (TBG) that carries approximately 70%
of TH, transthyretin (TTR) which binds about 10% to 15% of the hormone, and
albumin that binds 15% to 20% of T4 and T3. Several other serum proteins
bind T4 and T3 as well as reverse T3 (rT3), but their contribution to the over-
all hormone transport seems negligible in both physiological and pathological
situations. In particular, lipoproteins transport a minor fraction of T4 and T3
through specific interaction with various apolipoproteins (for review see [314]).
In the CSF, TTR is the major TH-binding protein.
T4, the most common form of TH in circulation, is carried to different organs
and tissues where it is locally converted into T3. A large proportion of the T3
in circulation is produced outside of the thyroid gland in the liver and kidney
by the action of type I deiodinase (DIO1). In the brain, T3 is produced locally
by the action of type II deiodinase (DIO2). Inactivation of TH is carried out by
the action of type III deiodinase (DIO3), that converts T4 into rT3 and T3 into
T2 that have little or no biological activity, and by glucoronosyltransferase and
sulfotransferase enzymes that participate in TH elimination process [207].
The effects of THs are mostly mediated by nuclear TH receptors (TRs)
1.2 Retinoids and thyroid hormones 29
which are T3-responsive transcription factors. The active TRs bind to their
specific TH response element (TRE) in the regulatory regions of target genes
in two different ways, as homodimers or as heterodimers with RXR, activating
or repressing the expression of several target genes [416, 104]. THs have
been shown to directly control the expression of more than 50 genes [100].
No tissue or organ other than the thyroid has been shown to produce TH.
Its synthesis is regulated by the hypothalamus-pituitary-thyroid axis, via a feed-
back mechanism depicted in the upper half of Figure 1.4.
The hypothalamus produces thyrotrophin-releasing hormone (TRH) which
is then transported to the pituitary gland, promoting production and release
of TSH. Subsequently, TSH stimulates the thyroid gland to produce TH. The
increase of TH levels in circulation has a negative feedback effect on the pitu-
itary, reducing its response to TRH. Conversely, when circulation levels drop,
the pituitary’s response to TRH increases, leading to increased TSH release.
Additionally, this regulatory loop is affected by internal and external factors
that alter the rate at which TSH is secreted [329]. For example, exposure to
low environmental temperatures may stimulate the release of TSH by adjusting
TRH secretion. Increased levels of somatostatin, dopamine, cytokines, and
glucocorticoids reduce secretion of TSH. Estrogens have the opposite effect,
increasing TSH.
As we discussed earlier, inadequate supply of iodine leads to inadequate
TH production and, therefore, TH function ultimately depends on an adequate
supply of iodine to the gland. Inadequate supply of iodine raises the levels of
TSH secretion which in turn stimulates TH synthesis and release. In particular,
intrathyroidal deiodination increases when the thyroid is stimulated by TSH,
leading to the release of a large amount of T3, which is the biologically active
metabolite of THs [53].
Levels of free TH in serum are directly related to the amount of hormone
entering the cell. Therefore, concentration of the free T4 and T3, rather than
the total TH, is usually a more accurate indicator of the activity level of TH-
dependent cell processes [314].
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1.2.5 Retinoids and thyroid hormones as biochemical ba-
sis for the neurodevelopmental hypothesis of schizo-
phrenia
Many similar characteristics exist between the modes of action of retinoids
and THs, and between their metabolisms. The main mechanism of action of
both is their regulatory influence on the expression of several target genes
upon interaction with nuclear receptors. As we discussed before, TTR is a
major carrier of TH in the CNS and also forms a complex with retinol-binding
protein. Therefore TTR participates in the homeostasis of both retinoids and
THs. Interestingly, besides belonging to the same family of nuclear receptors,
RXR and TR often heterodimerize. Both retinoids and THs are involved in the
regulation of processes such as differentiation of the cerebellum, axonal mi-
gration and myelination [317], and the control of lateralization and symmetry
of the embryo [383, 382]; processes that have been implicated in schizophre-
nia [293]. Among the genes regulated by retinoids and THs are those that
encode myelin basic protein [317], dopamine receptor D2 [327] and neureg-
ulin 1 receptor, ERBB4 [285], which have all been implicated in schizophrenia.
In view of these similarities, the previously proposed retinoid hypothesis of
schizophrenia [125] has recently been extended to THs [293].
Since retinoids and THs are essential for numerous neurodevelopmental
processes associated with schizophrenia, abnormal function of these two “en-
docrine systems” could play a role in the disease etiology. The enzymes and
other proteins that regulate both TH and retinoid metabolism are genetically
determined, but their availability is dependent on supply of vitamin A and io-
dine acquired from the environment. Therefore, retinoids and THs might offer
a candidate functional link between the identified genetic and environmental
risk factors in schizophrenia (see Figure 1.5).
The search for evidence that would support the involvement of TH and
retinoids in schizophrenia could include studies of plasma TH and retinoid lev-
els in patients compared with controls, but also genetic association studies.
The effects of retinoids and THs are dependent on the quantity of retinoids
and TH reaching the tissues and the availability of the correspondent recep-
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Figure 1.5: Retinoids and thyroid hormones may provide a functional link between genetic
and environmental risk factors in the neurodevelopmental hypothesis of schizophrenia.
tors in the cell nuclei. Retinoid and TH metabolism could be altered by the
presence of genetic variants in genes which would result in abnormal activity
of a transporter, an enzyme, or other proteins which regulate their metabolism.
DNA variants that occur frequently in the population are known as “poly-
morphisms” and they are linked with modest but true biological effects. Their
abundance in the human genome as well as their high frequencies in the hu-
man population justify the idea that they can explain variations in the risk to
common diseases, as we will explain in Section 1.3.2.
1.3 Molecular genetics studies in schizophrenia
research
Identification of schizophrenia susceptibility genes has proven to be an ex-
tremely difficult task. This is due to clinical heterogeneity, a complex and un-
certain mode of inheritance, effects of incomplete penetrance, the involvement
of non-genetic factors, and the likely large number of susceptibility genes con-
tributing each with a small risk only. Currently, linkage and association studies
together with robust statistical methods, as well as gene expression analysis
are being used to identify schizophrenia genes.
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1.3.1 Linkage studies
The literature on schizophrenia linkage studies is particularly extensive and
complex, replete with attractive original observations and subsequent studies
that fail to replicate initial findings. These apparent discrepancies may, in fact,
reflect the complex nature of schizophrenia.
Classical linkage studies analyze the segregation of markers along with
the disease phenotype and require large pedigrees with several affected mem-
bers. If, in a family, all affected individuals present a particular marker pattern,
different than the ones showed by unaffected individuals, the chromosomal
region in the vicinity of the marker represents a potential region for mapping
disease-related genes. Subsequently, more markers must be tested to narrow
the region of interest and to eventually identify the causative gene. Application
of molecular biology techniques in combination with statistical linkage analysis
has been highly effective in identifying rare variants in high risk genes, such
as the ones involved in single-gene, Mendelian disorders [46].
Because of their power in identifying loci for classical Mendelian disor-
ders, linkage studies have been extensively used in the attempt of identify-
ing genes underlying multifactorial (non-Mendelian) diseases [46]. In these
complex traits, although it is unlikely that uncommon high risk genes are re-
sponsible for disease susceptibility in the general population, they can possibly
be identified in specific samples of large families with multiple affected mem-
bers. Several strategies have been used in schizophrenia linkage studies in
order to improve the discovery of positive results. Nuclear families and sib-
pair linkage studies have been performed, both in general populations and in
geographically or ethnically isolated populations, in which there may be less
genetic heterogeneity due to a founder effect. To avoid the specification of
the mode of inheritance, nonparametric statistical analyses have been em-
ployed instead of parametric ones [371]. To avoid clinical heterogeneity, the
genetic study of schizophrenia can be simplified by focusing on specific inher-
ited features of the disorder, such as the endophenotypes mentioned earlier
(see Section 1.1.2). Despite all the efforts, and in contrast with other complex
disorders, such as Alzheimer’s disease or breast cancer, linkage studies so
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far have failed to pinpoint large single-gene effects. This is actually consistent
with the epidemiological evidence, suggesting that the existence of a single
locus accounting for most of the genetic susceptibility in schizophrenia is very
unlikely. In addition, the frequent non-replication of initial reports has been in-
terpreted as an indication that linkage analyses are not reliable in the detection
of genes of small effect [313].
Technological improvements in the identification and genotyping of poly-
morphic DNA markers have increased the ability to genetically map complex
disorders. Large collaborative efforts have been undertaken in order to study
much bigger samples, which facilitates the detection of susceptibility genes
of moderate effect [36]. While the number of genome scans increases as
well as the sample sizes used, replicated linkage to several chromosomal
regions are starting to accumulate. Recently, two meta-analyses of all pub-
lished whole-genome linkage scans, using different statistical methods, have
obtained somewhat overlapping results [22, 209]. The Badner and Gershon
study supports the existence of susceptibility genes on chromosomes 8p, 13q,
and 22q [22]. The Lewis meta-analysis also identifies 8p, and 22q as suscep-
tibility regions as well as 1q, 2q, 3p, 6p, 11q, 14p, and 20q [209]. Interestingly,
in this last study the stronger linkage was found in chromosome 2q, a region
that had not previously been reported.
The 22q11 region has received particular interest based on estimations
that around 25% to 30% of velo-cardio-facial syndrome (VCFS) patients, which
present a deletion on this chromosome region, develop schizophrenia as they
reach adulthood [25, 302, 274]. The high prevalence of schizophrenia in this
group and the observation that 22q11 deletion is present in 2% of schizo-
phrenic patients [178] along with reports of linkage to 22q11 [22, 209] suggest
that this chromosome region might harbor a gene or genes relevant to the
etiology of schizophrenia [16].
In summary, the linkage data in schizophrenia demonstrate several fea-
tures that were already predicted on the basis of genetic epidemiological find-
ings [310]. Existence of a major risk locus is highly unlikely, and the level of
statistical significance implicating a number of regions is consistent with the
presence of several genes of moderate effect. Finally, the chromosomal re-
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gions of interest are typically broad.
Positive linkage results are only proved to be true when the disease gene(s)
are identified. To identify genes in regions for which positive linkage results
have been obtained, association studies are increasingly performed to follow
up on linkage evidence.
1.3.2 Association studies
The use of association rather than linkage studies seems a simpler and more
powerful approach to detect genes of small effect [261, 312]. The common ap-
proach to detect association is the case-control design, in which the frequency
of a specific genetic marker is compared between affected and unaffected in-
dividuals. The main advantage of this design is that it makes use of unrelated
individuals, which are relatively easy to recruit. The main weakness is the
high rate of false-positives that can be obtained due to inappropriate selection
of controls [153]. This phenomenon may occur in the case of population strat-
ification (or admixture), where cases and controls, taken from a population in
which different genetic backgrounds are present, do not have the same propor-
tion of individuals from the various backgrounds. In this situation, false positive
results will be obtained if the trait is more prevalent in one of the genetic groups
and the frequency of genetic markers is not the same in all groups.
This limitation of case-control association studies prompted the develop-
ment of family-based designs that use unaffected siblings as controls or re-
construct the “control” using the non-transmitted parental alleles. However,
familiar relations imply that cases and “controls” will present high genetic simi-
larity (overmatching) and, consequentially, family-based studies are less pow-
erful when compared to well-designed case-control studies.
Association studies have been frequently applied to the study of candi-
date vulnerability genes. These candidate genes can be selected for various
reasons: because they are located on a chromosomal region previously im-
plicated in the etiology of schizophrenia by linkage studies; their expression
is altered in postmortem brain tissue of schizophrenic patients; they are impli-
cated by animal models of schizophrenia; or, finally, they belong to metabolic
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or signaling pathways hypothesized to be changed in schizophrenia.
Although no susceptibility gene for schizophrenia has consistently been
detected, several strong candidate genes have recently been identified. Most
of these genes are located on chromosomal regions previously implicated by
linkage studies, such as neuregulin 1 (NRG1) in chromosomal region 8p21-
22 [351], dysbindin (DTNBP1) in 6p22.3 [353], D-amino acid oxidase acti-
vator (DAOA or G72) in 13q22-34 [64], RGS4 in 1q21-22 [63], calcineurin
gamma subunit (PPP3CC) in 8p21.3 [114], trace amine receptor 4 (TRAR4)
in 6q23.2 [82], and catechol-O-methyltransferase (COMT ) and proline de-
hydrogenase (PRODH) in 22q11 [212, 342]. Many of these studies have
been replicated. In addition, some of these genes were found to be dif-
ferentially expressed in postmortem schizophrenic brains as is the case for
NRG1 [199], DTNBP1 [360, 395], RGS4 [253], and COMT [230]. To make a
strong case, functional studies must be carried out for each implicated gene,
in order to explore whether it affects developmental and behavioral charac-
teristics of relevance to schizophrenia. For example, for PRODH and cal-
cineurin, transgenic mice have displayed changes in “schizophrenia-like” be-
haviors [417, 255, 122].
It should be noted that none of these promising candidate genes, with the
exception of COMT, have been linked with a DNA variant capable of changing
gene function or expression. Even for the two genes with highest replication
ratios (DTNBP1 and NRG1), important questions remain. No single high-risk
haplotype is associated across all samples. This can possibly be caused by
the presence of multiple susceptibility alleles or by the fact that a single risk
allele is carried on a large diversity of haplotypes, even in closely related popu-
lations. It is possible that multiple variants in a particular gene all cause similar
liability to the disease. If, in fact, schizophrenia has appeared early in the
evolution of modern Homo sapiens [30], a single primordial variant may have
been extensively shuffled by recombination, yielding haplotypes that are differ-
entially represented in different populations. Evidence exists supporting such
haplotype differences for some genes even among closely related Northern
European groups [306].
An exciting observation is that most of the associated genes encode pro-
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teins that can be directly related to the schizophrenia pathophysiology via mod-
ulation of glutamatergic neurotransmission [142].
1.3.3 Gene expression studies
The recent development of commercial RNA expression platforms (microar-
rays) allows the screening of tens of thousands of genes in a relatively short
period of time, requiring relatively small amounts of biological material. These
microarray studies provide a high-throughput methodology to identify differen-
tially expressed genes between ill and healthy persons, and to measure the
activity and the effect of several drugs or pathogens on different types of cells
and tissues. Changes in mRNA expression can result in phenotypic differ-
ences, though this is not always the case. Altered gene expression does not
always correspond to abnormal protein levels, even when measured in the
same group of brains [380, 187].
Microarray studies are primarily a screening tool. Their results must be val-
idated by more laborious methods such as in situ hybridization and real-time
polymerase chain reaction, which provide higher resolution. At the level of
individual genes little agreement has been achieved between microarray stud-
ies. There are even cases of genes whose expression have been reported
increased in some studies and decreased in others [250, 134]. These discrep-
ancies can in part be explained by technical differences between studies, such
as the selection of genes present in the array, quality of brain tissue, number of
individuals studied, microarray producer, and bioinformatics protocols applied
in the analysis.
Several studies analyzing genome-wide expression in the brain have iden-
tified a high number of genes differentially expressed in schizophrenic patients
compared with mentally healthy individuals [380, 252, 247, 134]. Biological
validation of microarray results must be conducted to investigate whether the
alteration in gene expression actually represents the cause of the disease, or
results from the disease pathophysiology or from chronic medication.
Apart from identifying individuals genes, microarray studies have the ca-
pacity to detect alteration in expression patterns of multiple genes, leading
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to the identification of relevant metabolic and signaling pathways involved in
schizophrenia. In fact, a number of gene networks have been detected to
be affected in schizophrenia. Among these are oligodendrocyte- and myelin-
related genes [364], and networks that control pre-synaptic function [252],
neurochemical impairment of synapses [166], synapse formation and prun-
ing [251], neuronal migration [65], gene transcription regulation [365], and G-
protein signaling [251]. These altered pathways, although requiring biological
and clinical validation, provide insights into the schizophrenia etiology, and
give rise to new working hypotheses.
In summary, the combination of linkage, association, expression, and func-
tional studies is expected to provide answers in the search for the genes un-
derlying the schizophrenia etiology.
38 General introduction 1
2
Research objective and strategy
40 Research objective and strategy 2
The general objective of the work reported in this thesis was to investigate
whether retinoids and THs are related to the pathophysiology of schizophrenia.
In other words, to search for evidence that may help to support or disprove the
theory explained in Section 1.2. Our search strategy consisted of the following
steps.
Propose functional candidate genes. To propose candidate genes, we
studied literature on genes related to TH and retinoid metabolisms, including
their transporters, their nuclear receptors, enzymes involved in their synthesis,
and on genes whose transcription they regulate. In particular, we focused on
genes that have somehow been functionally related to schizophrenia.
Search for DNA variants in selected candidate genes. To find DNA vari-
ants in the selected genes we searched for known variants reported in the
literature or deposited in human genome databases. Additionally, in order
to find novel variants, we applied molecular techniques on DNA samples of
schizophrenic patients, such as Single Strand Conformational Polymorphism
(SSCP) analysis and sequencing.
Genotype selected variants in appropriate samples. Based on character-
istics of the DNA variants found, such as their frequency and their pair-wise
linkage disequilibrium (LD), we selected several variants in each candidate
gene. We then genotyped the selected variants in samples from different ge-
ographic locations and corresponding to different study designs (case-control
and parent-patient triples).
Analyze the obtained data to establish whether association exists be-
tween the variants and schizophrenia. We applied appropriate statistical
tests to the obtained genotypic and corresponding diagnostic data to establish
whether significant associations exist between particular DNA variants and
schizophrenia.
In the remainder of this thesis, we report on the study of each of the selected
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Table 2.1: Studied candidate genes.
Gene Transport Receptor Transcription Schizophrenia
partner regulated by abnormality
NR4A2 - RXR - Dopamine transmission
PTGDS TH - TH Lipid metabolism
Retinoid Retinoid
TTR TH - - (Behavior)
Retinoid
NRGN - - TH Glutamate transmission
Retinoid
functional candidate genes (see Table 2.1). For each of these genes, we stud-
ied the association of several DNA variants with schizophrenia.
The NR4A2 gene, studied in Chapter 3, forms heterodimers with retinoic
X receptor (RXR) and has been related with dopamine transmission, known
to be abnormal in schizophrenia. For this gene, six rare variants have been
described in the literature, and we investigated their presence in a Portuguese
and a Brazilian sample of schizophrenic patients and controls.
The lipocalin-type of prostaglandin D2 synthase (PTGDS) is not only trans-
porter of both TH and retinoids, but its expression is also regulated by them.
PTGDS is related to lipid metabolism, which is known to be abnormal in schizo-
phrenia, and is studied in Chapter 4. We studied the possible association of
three variants of PTGDS with schizophrenia in two case control samples, one
from the Portuguese mainland and one from Brazil, and in a parents-patient
sample from the Azorean islands.
TTR is a transporter of both THs and retinoids, and is studied in Chap-
ter 5. We searched for association of two polymorphisms in the TTR gene
with schizophrenia in the same three samples. We also analyzed the circulat-
ing levels of TTR itself and of RBP, which is transported by TTR.
The Neurogranin gene (NRGN) is studied in Chapter 6. The expression of
NRGN is regulated by THs and retinoids, and it is related to the transmission of
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glutamate, believed to be implicated in schizophrenia. We studied association
of three variants of NRGN to the disease in the two case-control samples and
in the parents-patient sample.
As we will see, the study of NRGN, in particular, has provided interesting
results in the context of the schizophrenia etiology.
Apart from association studies, evidence for the involvement of retinoids
and THs in schizophrenia could be obtained through studies of their plasma
levels in patients and healthy individuals. Though not central to this thesis, we
report on a preliminary study of this kind in Chapter 7, where serum levels of
five TH indicators (total and free T4, total and free T3, and TSH) are measured
in the male-subsample from the Portuguese mainland.
In Chapter 8, we summarize and discuss the relevance of the various re-
sults obtained, and we provide suggestions for future work.
3
Nur-related receptor 1 and
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This chapter was published as: Ruano D, Macedo A, Dourado A, Soares MJ, Va-
lente J, Coelho I, Santos V, Azevedo MH, Goodman A, Hutz MH, Gama C, Lobato
MI, Belmonte-de-Abreu P, Palha JA, NR4A2 and schizophrenia: lack of association
in a Portuguese/Brazilian study, Am J Med Genet B Neuropsychiatr Genet (2004)
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Abstract
The present study investigates the association of mutations in the nu-
clear receptor NR4A2 with schizophrenia. The human Nur-related re-
ceptor 1, NR4A2, is an orphan nuclear receptor that can be constitu-
tively active as a transcription factor and for which no natural ligand has
yet been identified. Alone or with the retinoid X receptor, RXR, NR4A2
influences the expression of several genes important for human brain
development and regulation. In the absence of Nurr1 (the mouse homo-
logue to human NR4A2), ventral mesencephalic dopaminergic mouse
neurons evidence severe developmental failure, a condition that is lethal
soon after birth. Nurr1 involvement in the dopaminergic system makes it
a good candidate for study in neuropsychiatric disorders such as schizo-
phrenia and Parkinson’s disease. Evidence by others support this hy-
pothesis: 1) mapping of the NR4A2 gene to chromosome 2q22-23, a
region with suggestive linkage to schizophrenia and 2) identification of
mutations in patients with schizophrenia (c.366-369delTAC, c.308A>G,
c.-469delG), manic depression (c.289A>G) and familial Parkinson’s dis-
ease (c.-291delT, c.-245T>G). To further extend these observations, we
searched for all these mutations in 176 Caucasian Portuguese and 82
Caucasian Brazilian subjects with lifetime diagnosis of schizophrenia.
The study failed to identify any of the described mutations in patients or
controls. Nevertheless, these negative results do not exclude altered ex-
pression of nuclear receptors in schizophrenia or the presence of other
mutations.
3.1 Introduction
Schizophrenia is a chronic psychotic disorder of unknown etiology. Twin and
family studies demonstrate a genetic basis for the disease [372]. Several
genome wide studies identified chromosome loci consistently linked to in-
creased susceptibility to schizophrenia in different populations [209]. Despite
the evidence for genetic predisposition, the lack of concordance in monozy-
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gotic twins implies that an epigenetic environmental effect is required for dis-
ease onset [372]. For this reason, interest has been raised in hypotheses
bridging both genetic and environment-related mechanisms. Environmental
factors such as hormones and vitamins interact with different nuclear receptors
and interfere with the transcription of several genes in a developmental regu-
lated fashion. Among these are the retinoids, considered good candidates be-
cause of genetic linkage studies implicating schizophrenia with dysregulation
of the retinoid cascade and/or genes whose expression they regulate [125].
The genes for dopamine-2 receptor, synapsin and dopamine -hydroxylase
are among those whose expression requires activation by retinoids [327, 184,
185, 23]. Pharmacological, histological and brain imaging data have for long
implicated dopaminergic dysfunction in the etiology of schizophrenia. Reti-
noid availability can, therefore, interfere with susceptibility to schizophrenia,
either directly, through the dopamine system, or indirectly through molecules
involved in its development and/or regulation. Interestingly, retinoid analogs
have been suggested in the treatment of schizophrenia, alone or in combina-
tion with dopamine receptor agonists [66].
RA receptors belong to the steroid/thyroid hormone nuclear receptor su-
perfamily that includes several orphan receptors for which no ligands have
been identified. These receptors often act as heterodimers greatly increas-
ing the complexity of gene regulation. NR4A2, one of these orphan nuclear
receptors, is known to regulate transcription of target genes in two different
ways: alone, as a monomer, or as a partner with the retinoid X receptor
(RXR) [295, 391].
Nurr1 (the mouse homologue to human NR4A2 gene) mRNA is expressed
very early in the ventral midbrain [419, 418] and disruption of its expression
is responsible for massive failure to generate dopaminergic neurons in the
midbrain and causes death soon after birth [418, 328]. The lack of dopamin-
ergic neurons in the midbrain seems to be related with the inability to express
tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis [419].
Furthermore, Nurr 1 seems to retain its role in mature dopaminergic neurons,
since its expression continues over adulthood and is extremely impaired after
ventral mesencephalic dopaminergic neurons injury [419].
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These observations increased the interest in identifying precise molecular
and biochemical mechanisms of behavior regulation by NR4A2 in psychiatric
and neurological disorders. Furthermore, the 2q22-q23 chromosome region
that harbors the NR4A2 gene has suggestive linkage with schizophrenia in
various populations [260, 408, 75, 209]. In accordance to this hypothesis
several groups have looked for mutations in the NR4A2 human gene that could
increase susceptibility to schizophrenia. Up to date, two deletions and one
missense mutation have been described in schizophrenic patients and one
missense mutation has been found in manic-depressed individuals [44, 60]
while, recently, two mutations in the untranslated region have been identified
in patients with familial Parkinson’s disease [205]. These findings prompted us
to investigate all these NR4A2 mutations in a large sample of Portuguese and
Brazilian schizophrenic patients. Patients fulfilled DSM IV lifetime diagnosis
of schizophrenia, confirmed by OPCRIT diagnostic algorithm. None of the
mutations described in the literature were identified in this group of patients.
3.2 Materials and Methods
The sample consisted in 176 Portuguese (age range 15-74, average 34.0; 67
female and 109 male) and 82 Brazilian (age range 18-63, average 34.3; 10
female and 72 male) schizophrenic patients and 105 Portuguese (age range
19-79, average 35.5; 53 female and 52 male) and 85 Brazilian (age range
19-58, average 32.9; all men) mentally healthy individuals. All subjects were
unrelated Caucasians. Patients gave informed consent for the study, and ethic
committees of both institutions approved the study. All patients (Portuguese
and Brazilian) were classified by the OPCRIT system (Operational Checklist
for Psychotic Disorders) [237]. OPCRIT automated system gathered informa-
tion from all case records, including medical, nursing, social work and occu-
pational therapy notes together with data from clinical interview with patient
and relatives. Additionally, Portuguese schizophrenic patients received life-
time diagnosis using DIGS (Diagnostic Interview for Genetic Studies) as pre-
viously described [283]. Controls were from European origin or descent and
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free of any lifetime diagnosis of major mental illness and physical illness. Por-
tuguese controls received DIGS assessment and Brazilian controls were se-
lected among blood bank volunteer donors documented to be free of chemical
dependence [308]. All interviews and diagnostic formulations were performed
by one of the authors. Venous blood was drawn from all subjects and DNA
extracted using standard salting-out procedures.
For genotyping the c.-245T>G, c.289A>G, c.308A>G mutations and the
deletion c.-469delG, we followed PCR conditions previously described [44, 60,
205]. PCR products were analyzed on gel electrophoresis after digestion with
the restriction enzymes Ava II (Fermentas, Vilnius, Lithuania), ApaL I (Fermen-
tas), Tse I (New England BioLabs, MA, USA) and Cfr I (Fermentas), respec-
tively. The c.366-369delTAC deletion was screened by Single Strand Confor-
mation Polymorphism (SSCP) on the PCR product amplified with the primers
(5´-3´) CTTGTACCAAATGCCCCTGT and GAGACTGGCGTTTTCCTCT. Elec-
trophoresis on 10% non-denaturing polyacrylamide gel with 2.5% glycerol was
performed at 500 V for 2.5-3 hours. Temperature was strictly maintained
at 14oC. Samples from patient carriers of the mutations c.366-369delTAC,
c.289A>G and c.308A>G were used as controls.
Search for the c.-291delT on the PCR product amplified with primers pre-
viously described [205] was done by SSCP analysis on MDE gel (BMA, Rock-
land, USA) run at 4, 10 or 25oC.
3.3 Results
Using SSCP analysis, we searched the deletions c.366-369delTAC and c.-
291delT, looking also for other possible mutations [384] on the same PCR
product. Figure 3.1 shows the SSCP migration pattern of a c.366-369delTAC
deletion carrier. None of the samples tested revealed the presence of mutated
alleles.
For the c.-291delT deletion we analyzed one subpopulation of 60 Por-
tuguese schizophrenic patients and ran the SSCP at 3 different temperatures
to increase the rate of detection. Again, we failed to identify any mutation in
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Figure 3.1: SSCP of the NR4A2 exon 3 PCR fragment. On lane 8 run a sample containing
the c.366-369delTAC mutation. Lanes 1-6 correspond to Brazilian schizophrenic patients and
lanes 9-15 to Brazilian mentally healthy individuals.
the PCR product containing the position c.-291. Analysis of the mutations c.-
469delG, c.-245T>G, c.289A>G and c.308A>G was done by digestion with
the enzymes Cfr I, Ava II, ApaL I and Tse I for which a new restriction site
is present in the mutated allele. None of the samples, from schizophrenic or
mentally healthy individuals, contained any of the mutations screened.
Table 3.1 is a summary of all studies, including ours, in which NR4A2 mu-
tations described in diseases have been investigated.
3.4 Discussion
In the present study we investigated, for the first time, the presence of two
NR4A2 mutations recently identified in familial Parkinson’s disease [205] in
258 schizophrenic patients and 190 mentally healthy individuals. We also
searched for mutations in NR4A2 previously described in patients with schizo-
phrenia and manic-depression [44, 60]. No mutation was found either in pa-
tients or controls. Given the complex etiology of schizophrenia and the fail-
ure to identify a single causative gene, it is unlikely that any individual muta-
tion will be strongly represented in the patient’s population [56]. In the case
of transcription factors such as nuclear receptors, several different mutations
can impair proper function and influence the appropriate expression of sev-
eral genes. Therefore, for any new mutation found it is important to increase
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Table 3.1: NR4A2 Mutations Detected in Patients With Schizophrenia, Manic Depression,
and Parkinson’s Disease. Represented is the number of individuals in which NR4A2 mutations
were found among all patients tested. Transcription activity was measured by in vitro studies
(↓=Decreased, ↑=Increased, ? =Not determined).
Mutation Location Population
c.-469delG Promoter ? 2/176 Han Chinese schizophrenic [60]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasillan schizophrenic
c.-291delT Exon 1, ↓ 8/107 familial & 0/94 sporadic Parkinson’s (mostly Caucasian) [205]
untranslated 0/60 Caucasian Portuguese schizophrenic
c.-245T>G Exon 1, ↓ 2/107 familial& 0/94 sporadic Parkinson’s (mostly Caucasian) [205]
untranslated 0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
c.289A>G Exon 3, ↓ 0/135 Swedish schizophrenics [44]
coding 0/160 North American Caucasian schizophrenics [44]
0/70 Caucasian Swedish idiopathic Parkinson [44]
1/30 Caucasian Swedish manic depressed [44]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
c.308A>G Exon 3, ↓ 1/135 Swedish schizophrenics [44]
coding 0/160 Caucasian North American schizophrenics [44]
0/70 Caucasian Swedish Idiopathic Parkinson [44]
0/30 Caucasian Swedish manic depressed [44]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
c.366-369delTAC Exon 3, ↓ 1 childhood-onset/135 Caucasian Swedish schizophrenics [44]
coding 0/160 Caucasian North American schizophrenics [44]
0/70 Caucasian Swedish Idiopathic Parkinson [44]
0/30 Caucasian Swedish manic depressed [44]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
the size of the patient sample analyzed. The fact that we failed to identify the
mutations previously described in NR4A2 confirms that they are very rare.
Other studies have reported lack of association of NR4A2 polymorphic
variants in the promoter [52], 5´ and 3´ untranslated regions and intron 6
with schizophrenia [168, 170]. The human NR4A2 gene exists as a single
locus in human genome, covering 8.3 Kb in length, consisting of eight exons
and is mapped to chromosome 2q22-23 [164, 366]. This chromosome re-
gion has been implicated in schizophrenia [209]. The mutations c.289A>G,
c.308A>G and c.366-369delTAC, originate amino acid changes at the protein
level (M97V, H103R, and Y122, respectively) and result in decreased in vitro
transcriptional activity of NR4A2 dimers [44]. Decreased transcription activity
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of the NR4A2 is also described for the mutations in the 5´ untranslated region
found in patients with Parkinson’s disease [205]. Therefore, impaired tran-
scription activation of downstream target genes such as tyrosine hydroxylase
is expected in carriers of these mutant variants of NR4A2.
Studies in mice have revealed important functions for NR4A2 that clearly
suggest its possible involvement in several disorders of the central nervous
system in which the dopaminergic system has been implicated. Observa-
tions in Nurr1-null mice revealed that Nurr1 is requested for the formation of
midbrain dopaminergic neurons [418, 328] and that tyrosine hydroxylase, the
rate-limiting enzyme in the cathecolaminergic pathway, is absent in dopamin-
ergic neurons [418]. On the other hand, mice lacking the D2 receptors for
dopamine show increased Nurr1 expression in mesencephalic dopaminergic
neurons, suggesting that actions mediated by D2 receptors might be a con-
sequence of altered expression of Nurr1 [370]. In addition, Nurr1 enhances
the transcription of the human dopamine transporter gene [323], one of the
most specific phenotypic markers for dopaminergic neurons, and of the tyro-
sine hydroxylase gene [326, 184, 185]. Studies in Nurr1-null heterozygous
mice show that Nurr1 increases spontaneous locomotor activity in response
to stress [88]. The effect of amphetamines in Nurr1-null heterozygous loco-
motion remains controversial [88, 27].
These observations suggest that NR4A2 by itself, or through heterodimer-
ization partners, may participate in diseases with altered dopaminergic func-
tion such as Parkinson’s, schizophrenia and drug abuse. NR4A2 may also be
implicated in some personality traits with increased vulnerability to stress [88]
such as those in the schizophrenia phenotype spectrum. Both mutations asso-
ciated with decreased or increased NR4A2 activity and with altered regulation
of the NR4A2 gene throughout development might be associated with disor-
ders such as schizophrenia and Parkinson’s. Future studies must address
whether the expression of NR4A2 is altered in the brain of schizophrenic pa-
tients or influences their response to alcohol exposure or drug treatment. Bet-
ter understanding of the pathways involving NR4A2 might make it a potential
target for therapy with drugs like 6-mercaptopurine analogs or even stem-cell
transplants as recently suggested [286].
4
Lipocalin-type prostaglandin D2
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Abstract
Several observations point to the involvement of disturbed lipid biology
in schizophrenia. Reduced response to niacin flushing test, which in-
volves vasodilatation induced by prostaglandin D2 (PGD2), is among the
evidences, together with decreased CSF levels of lipocalin-type prosta-
glandin D2 synthase (PTGDS), the enzyme responsible for the synthe-
sis of PGD2 in the brain. Since PTGDS is also a carrier for lipophilic
molecules such as retinoids and thyroid hormones, altered PTGDS lev-
els might influence both PGD2-mediated signaling, and vitamin A and
thyroid hormone availability. To test whether genetic variants of PTGDS
are involved in the etiology of schizophrenia, we searched for variants in
the coding and regulatory regions of the gene. We identified four previ-
ously described polymorphisms. Using two case-control samples from
Portugal and Brazil, none of the polymorphisms tested was associated
with the disease. In addition, no transmission distortion was observed in
an independent parents-offspring sample from the Azorean Islands. Our
data do not support the involvement of the PTGDS gene in the etiology
of schizophrenia.
4.1 Introduction
Schizophrenia is a common mental disorder affecting about 1% of the world’s
general population [171]. Family, twin, and adoption studies indicate the pres-
ence of a large genetic component [239]. However, genetic linkage studies
have failed to identify a major risk chromosomal region [301]. The difficulty of
finding loci or genes underlying schizophrenia suggests involvement of several
genes, each conferring only a small degree of risk [347]. Association studies
are generally accepted to be the most powerful method for detecting genes of
small effect in complex disorders like schizophrenia [312].
Cumulative results support that schizophrenic patients have altered lipid
metabolism [101], including increased phospholipids breakdown and decreased
levels of polyunsaturated fatty acids, particularly arachidonic acid [414]. Arachi-
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donic acid and its products (e.g. prostaglandins) are critical to various signal-
ing pathways [35]. Interestingly, schizophrenic patients are reported to present
reduced response to niacin [159, 393, 345]. Flushing in response to niacin
(an acute allergic response) involves epidermal release of prostaglandin D2
(PGD2) [271, 270] which suggests the existence of an abnormal prostaglan-
din signaling. In addition, the flush response to niacin does not differ between
medicated and unmedicated schizophrenics [338] and is also impaired in non-
psychotic first-degree relatives of schizophrenic patients [386], suggesting that
the alteration in niacin sensibility is a genetic trait independent of medication
status. Underlying the abnormal niacin response might be decreased levels
of arachidonic acid [101] or impaired activity of the enzyme responsible for the
synthesis of PGD2.
There are two distinct types of enzymes, encoded by different chromo-
somes, responsible for PGD2 synthesis [376, 375, 374]. The hematopoietic-
type PGD2 synthase, encoded on 4q22.3, is responsible for the production
of PGD2 in the periphery and the lipocalin-type is responsible for the pro-
duction of PGD2 in the brain. Lipocalin-type PGD2 synthase (PTGDS), also
designated as β-trace, is produced in the leptomeninges and the choroid
plexus [33, 412], and is abundant in the cerebrospinal fluid (CSF). The sug-
gestion of altered PGD2 in schizophrenia makes PTGDS a good candidate
gene in schizophrenia, although it is unknown whether schizophrenic patients
display altered prostaglandin signaling inside the brain. The gene is composed
of seven exons located on chromosome 9q34.3 [400], a potential susceptibil-
ity region for schizophrenia [180]. In addition, PTGDS presents a distal thyroid
hormone response element (TRE) [401] and several indications suggest the
involvement of genes whose expression is regulated by thyroid hormones in
schizophrenia [293, 125]. In accordance, altered gene expression might ex-
plain the decreased levels of PTGDS described in the CSF of schizophrenic
patients [139, 137, 138].
To test whether genetic variants in the PTGDS increase susceptibility to
schizophrenia, we screened all exons, exon-intron boundaries and the pro-
moter of the gene. In order to determine whether the identified variants pre-
dispose individuals to develop schizophrenia, association studies were per-
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formed using two case-control samples. To overcome the possible existence
of population stratification in those samples, we also performed a family-based
association study on an independent parents-offspring sample.
4.2 Materials and methods
4.2.1 Samples
Two case-control samples were used: one from Portugal and one from Brazil.
The Portuguese sample consisted of 244 cases (175 males and 69 females)
and 210 unrelated controls (131 males and 79 females) from northern and
central Portugal. The Brazilian sample consisted of 69 cases and 85 controls,
all unrelated males from Southern Brazil (Porto Alegre). A third, independent
sample consisting of 73 patients (48 males and 25 females) and their parents
from the Azores Islands, was used for family-based association analysis. All
subjects were of European ancestry, based on the individuals’ report of their
parents’ ethnicity. All participants gave informed consent for genetic studies,
and ethic committees of the institutions involved approved the study.
All patients from Portugal-mainland and Azorean Islands, as well as 45%
of the Portugal mainland controls and 67% of the Azorean parents were evalu-
ated using the Diagnostic Interview for Genetic Studies (DIGS) [283], a semi-
structured interview that assesses the criteria for schizophrenia and other psy-
chiatric diseases. The diagnosis was made based on the Diagnostic and Sta-
tistical Manual of Mental Disorders, review of the third edition (DSM-IIIR) [11].
All Brazilian patients were classified using the Operational Checklist for Psy-
chotic Disorders (OPCRIT) [237]. The Brazilian controls (blood donors) as
well as the remaining Portuguese controls (students and tissue donors) and
Azorean parents were collected without specific psychiatric evaluation (only
with the identification of healthy status).
4.2.2 Polymorphism screening and genotyping
The human PTGDS DNA sequence was retrieved from the NCBI GenBank
(http://www.ncbi.nlm.nih.gov/Genbank/), with the accession number NT 024000.
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Primers for PCRs were designed using the software Primer3 [319].
Using Single Strand Conformational Polymorphism (SSCP) analysis, a sub-
sample of 60 patients from the Portuguese mainland was used for screen-
ing DNA variants in the promoter, all seven exons, and intronic sequences
adjacent to exons in the PTGDS gene. The genotyping was done using a
chip-based MALDI-TOF mass spectrometry platform (SEQUENOM, inc., San
Diego, CA). We followed the same SSCP and MALDI-TOF approach previ-
ously described in detail by some of the authors [320]. The sequences of the
PCR primers used are available upon request.
4.2.3 Statistical analysis
Student’s t-test was used to compare age distributions between patients and
controls. Hardy-Weinberg equilibrium and gender distribution were assessed
using Chi-square (χ2) test.
Linkage disequilibrium (LD) between pairs of loci was evaluated by r 2. The
r 2 measure represents the statistical correlation between two sites, and takes
the value of 1 if only two haplotypes are present. There is a simple inverse
relationship between r 2 and the sample size required to detect association be-
tween susceptibility loci and single nucleotide polymorphisms (SNPs) [387].
The r 2 values were computed using the ldmax program from the GOLD soft-
ware package [2].
Haplotypes were reconstructed using PHASE, version 2.1 [352].
Global genotypic and haplotype distributions (2 × N contingency tables)
were compared between patients and controls by χ2 test. Allele and specific
genotype and haplotype frequencies (2 × 2 contingency tables) were com-
pared between these two groups by Fisher’s exact test. Fisher’s exact test
is the usual choice for testing the significance in association studies and it is
believed to be the most reliable test when one or more of the expected num-
bers in the 2 × 2 table is less than five, and when the overall sample size is
small [177]. χ2 test, Fisher’s exact test, and P-values were computed by InStat
3.06 (GraphPad Software).
Transmission disequilibrium test (TDT) was applied to analyze the results
of the family-based association study (Azorean trios sample) using TRANS-
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Figure 4.1: Genomic structure of the human PTGDS gene and location of the four SNPs
detected. Black boxes represent protein-coding regions, white boxes represent untranslated
regions, and the dashed line represents the thyroid hormone response element (TRE). Lo-
cations of initiation (ATG) and stop (TAG) codons and sizes of introns and exons are also
shown. The rs numbers identifying the SNPs are in accordance with the dbSNP database
(http://www.ncbi.nlm.nih.gov/SNP/).
MIT, version 2.5.4 [67]. This program computes both global P-values, which
estimate the significance of transmission distortion for all the haplotypes tested,
as well as individual P-values for the significance of transmission distortion of
specific haplotypes. All tests were two-tailed and results were considered to
be significant if the P-value was less than 5%.
4.3 Results
Using SSCP, we screened the PTGDS gene in 60 schizophrenic patients
and identified four SNPs that have been previously recorded in the NCBI db-
SNP database (http://www.ncbi.nlm.nih.gov/SNP/). The rs7858965 SNP is lo-
cated in the promoter region (80bp downstream from the thyroid hormone re-
sponse element), rs4880179 is a synonymous change on exon 1, and rs6926
and rs13306 lie in the non-coding exon 7 (Figure 4.1). Applying r 2 analysis,
which measures the correlation between alleles, to genotype data generated
by the SSCP screening (60 schizophrenic patients from Portugal mainland)
we estimated that the rs7858965 and rs4880179 variants were in complete LD
(r 2=1.0 and P-value<0.001). Due to the complete LD, only one of these vari-
ants (rs4880179) was genotyped in the complete samples described above.
Analysis of gender distribution in the Portuguese mainland sample showed
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Table 4.1: PTGDS SNPs genotyped in case-control samples. Represented are the frequen-
cies of the minor allele.
SNP ID Alleles Sample Frequency HWE
major>minor origin Cases Controls (overall)
rs4880179 G>A Portugal mainland
Brazil
0.037
0.015
0.044
0.031
0.731
0.769
rs6926 C>A
Portugal mainland
Brazil
0.267
0.313
0.278
0.280
0.608
0.460
rs13306 A>G
Portugal mainland
Brazil
0.035
0.014
0.043
0.035
0.684
0.741
that males are significantly (P-value=0.034) more frequent in cases (71.7%)
than in controls (62.4%). Age distribution was well matched between pa-
tients and controls for both Portuguese mainland and Brazilian samples (P-
value>0.4 for both samples). The same was true after the Portuguese main-
land sample was stratified by gender (P-value=0.232 for males and P-value=
0.443 for females).
None of the three SNPs’ genotype distribution showed any significant de-
viation from Hardy-Weinberg equilibrium, either in controls, patients, parents
or overall groups.
Genotype and allele frequencies at the three SNPs analysed did not differ
significantly between the schizophrenic patients and the controls either in the
Portuguese mainland or in the Brazilian samples (Table 4.1).
Haplotypes were estimated by PHASE from the genotypic data. Two ma-
jor haplotypes, among the 6 estimated, showed a frequency>5% (Table 4.2).
They accounted for more than 95% of the estimated haplotypes in patients
and controls, both in the Portuguese-mainland and Brazilian samples. There
were fewer haplotypes than can be expected from three SNPs (23=8), indi-
cating existence of linkage disequilibrium across the alleles analysed. Based
on r 2, the SNPs rs4880179 and rs13306 are tightly correlated (r 2 >0.75 and
P-value<0.001 for all samples). These two SNPs are poorly correlated with
the rs6926 SNP (r 2 approximately 0.1).
There were no significant differences in haplotype distributions (Table 4.2)
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Table 4.2: Estimated haplotype frequencies and significance of association in the case
control samples.
Sample size (%)
Haplotypesa rs4880179 rs6926 rs13306 Cases Controls P-valueb
Portugal-mainland n=480 n=410
1 G C A 351 (73.1) 296 (72.2) 0.763
2 G A A 111 (23.1) 97 (23.7) 0.874
3 A A G 17 (3.5) 17 (4.1) 0.727
Global 0.876
Brazil n=130 n=160
1 G C A 89 (68.5) 114 (71.3) 0.609
2 G A A 39 (30.0) 41 (25.6) 0.430
3 A A G 1 (0.8) 5 (3.1) 0.229
Global 0.287
aHaplotypes formed by the 3 SNPs genotyped were reconstructed with the Phase program.
Haplotypes with an estimated probability less than 1% are not reported.
bP-value was assessed using Fisher’s exact test with the exception of the global P-value that
was obtained by χ2 test with 2df. Fisher’s exact tests were derived from a series of simple
2 × 2 tables based on the frequency of each haplotype versus all others combined between
the case and control groups.
between cases and controls in either the Portuguese mainland or the Brazil-
ian sample. This was also true after gender stratification of the Portuguese
mainland sample.
TDT results were concordant with the results of case-control association
studies since no excess of transmission was observed from parents to off-
spring in the 73 parents-offspring sample from the Azorean Islands (Table 4.3).
4.4 Discussion
Our results do not support the hypothesis that inherited variants in the PTGDS
gene are involved in the etiopathophysiology of schizophrenia. By screening
all exons, intron-exon boundaries and most of the promoter region, we found
four polymorphisms already identified in the dbSNP database and none of the
variants tested is associated with schizophrenia.
4.4 Discussion 59
Table 4.3: Estimated haplotype frequencies, and P-values for haplotype transmission cal-
culated with the TRANSMIT program.
Haplotype
Haplotype rs4880179 rs6926 rs13306 Observed Expected P-value
1 G C A 101 101.48 0.887
2 G A A 38 37.52 0.888
3 A A G 5 4.98 0.909
4 A A A 0 0.50 0.262
5 A C A 0 0.52 0.259
6 G A G 2 1.00 0.213
Global 0.550
However, we did not exclude that the studied DNA variants could be re-
lated to a particular symptom or feature of schizophrenia. In fact, Miwa stud-
ied hypertensive patients and found an association of the rs6926 AA geno-
type of the PTGDS gene with an increase in cholesterol levels [254]. In-
terestingly, cholesterol levels are higher in schizophrenics when compared
with controls [173] independent of medication, giving additional evidence of
lipid metabolism dysregulation in these patients. The Miwa study has been
conducted in a Japanese population and we know from the HapMap project
(http://www.hapmap.org/) that the frequency of the rs6926 AA genotype is
somewhat different in the Japanese (0.023) and European (0.083) popula-
tions. Still, if the high levels of cholesterol found in schizophrenic patients
have a genetic basis and are not consequence of their medication, poor diet,
or of a more sedentary life we might expect to find a similar association of
PTGDS genotypes in our samples.
Since altered expression of genes could result not only from DNA variants
in the regulatory regions of genes but also from inadequate supply of modula-
tors of transcription activity [280], the fact that we failed to detect association of
the studied DNA variants with schizophrenia does not exclude that the PTGDS
expression levels could be altered in the brains of patients. It has been shown
that thyroid hormones [109, 110] and retinoids [175] modulate the expression
of the PTGDS gene. Abnormal availability of thyroid hormones and retinoids
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has been suggested to be involved in the etiology of schizophrenia [293, 125],
and such abnormalities could explain the low CSF level of PTGDS reported in
these patients [139, 137, 138].
Consequences of altered PTGDS levels are not known, but given the im-
portant roles proposed for the PTGDS enzyme and its product, PGD2, the
altered expression of the PTGDS gene may contribute to the multitude of bi-
ological abnormalities observed in the schizophrenia pathology. For instance,
studies in rodents have shown that PTGDS plays an important role in the reg-
ulation of sleep-wake cycles [359, 231] and in sensitivity to tactile pain [89],
which are both known to be altered in schizophrenic patients [90, 232].
Interestingly, the relation of PTGDS with thyroid hormones and retinoids
is reciprocal. On the one hand, these latter two control the expression of
the PTGDS gene. On the other hand, since PTGDS has been described as a
carrier for thyroid hormones and retinoids [362, 31], abnormal levels of PTGDS
can eventually disturb their availability for modulation of the expression of a
large number of genes, including PTGDS itself. In this way, PTGDS could
contribute to the deleterious effects of altered thyroid hormones and retinoids
in the central nervous system.
In conclusion, although we failed to detect involvement of PTGDS gene
variants in the genetic susceptibility to schizophrenia in the populations stud-
ied, it seems worthwhile to explore the effect of altered PTGDS levels as a
consequence of the modulation of transcription and its relationship with the
disease pathology.
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Abstract
It has been proposed that schizophrenia results from an environmental
insult in genetically predisposed individuals. Environmental factors ca-
pable of modulating transcriptional activity and their carriers could link
the genetic and environmental components of schizophrenia. Among
these is transthyretin (TTR), a major carrier of thyroid hormones and
retinol-binding protein (RBP). Retinoids and thyroid hormones regulate
the expression of several genes, both during development and in the
adult brain. Decreased TTR levels have been reported in the cere-
brospinal fluid of patients with depression and Alzheimer’s disease, and
the absence of TTR influences behavior in mice. DNA variants capable
of altering TTR ability to carry its ligands, either due to reduced tran-
scription of the gene or to structural modifications of the protein, may in-
fluence development of the central nervous system and behavior. In the
present study we searched for variants in the regulatory and coding re-
gions of the TTR gene, and measured circulating levels of TTR and RBP.
We found a novel single nucleotide polymorphism (SNP), ss46566417,
18bp upstream of exon 4. Neither this SNP nor the previously described
rs1800458 were found associated with schizophrenia. In addition, serum
TTR and RBP levels did not differ between mentally healthy and schizo-
phrenic individuals. In conclusion, our data does not support an involve-
ment of the TTR gene in the pathophysiology of schizophrenia.
5.1 Introduction
Schizophrenia is a complex neurodevelopment disorder [28]. Epidemiological
studies indicate an increased risk for developing schizophrenia in relatives of
probands with the disease [126], suggesting a genetic predisposition. How-
ever, monozygotic twins are frequently phenotypically discordant, which im-
plies that environmental factors must play a role in the disease etiology [372].
Thyroid hormones and retinoids are among the environmental factors pro-
posed to be altered in schizophrenia [125, 293]. It is widely recognized that
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thyroid hormones and retinoids are essential for the normal development of
the central nervous system, and that lack of adequate levels during pregnancy
leads to several neurological defects [195, 217, 267, 268, 406]. Thyroid hor-
mones and retinoids act as modulators of the expression of several genes
through the binding of retinoic acid and triiodothronine to the corresponding
nuclear receptors. Interestingly, evidence of altered retinoid and thyroid hor-
mone metabolisms in schizophrenic patients is arising from studies in postmor-
tem brains, in which RAR and myelin-basic protein, genes whose expression
is regulated by thyroid hormones and retinoids, were found to have altered
expression [134, 309].
By influencing ligand availability, carriers of thyroid hormones and retinoids
indirectly regulate the transcription of several genes. Among the modulators
of thyroid hormone and retinoid availability is transthyretin (TTR), a major car-
rier of thyroxine and retinol (through association with RBP], both in serum and
in cerebrospinal fluid (CSF) [292]. TTR has been implicated in behavior: de-
creased TTR CSF levels were found in patient) with depression [357] and with
Alzheimer’s disease [337]. Whether this decrease is the result or a conse-
quence of the disease or whether it is caused by medication is still unclear.
Supporting that both processes might be implicated in behavior are the obser-
vations that TTR-null mice [292] present increased motor activity in behavior
tests that address anxiety-like and depression-like behaviors [349], and that
clozapine treatment induces TTR expression in the brain [59].
The TTR gene is a single copy gene, on 18q12.1, composed of four ex-
ons [373] that encodes a 14 kDa subunit which assembles as a tetramer [32].
Whereas plasma TTR originates primarily from the liver, CSF TTR is mainly
produced and secreted from the choroid plexus, where it represents about
20% of the total protein synthesis [9]. The observation that homologues of the
TTR protein can be found in a wide range of species [94] and that its synthesis
starts early during embryonic development [197], suggests a relevant role for
TTR in development.
These observations, prompted us to investigate the TTR gene as a can-
didate gene in schizophrenia. In the present study we searched for variants
in the regulatory and coding regions of the TTR gene, and association be-
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tween the polymorphisms detected and schizophrenia were analyzed in three
different samples. We also investigated serum TTR and RBP levels in schizo-
phrenic and in mentally healthy individuals.
5.2 Materials and methods
5.2.1 Samples
Two case-control samples were used: one from Portugal-mainland and a sec-
ond from Brazil. A total of 244 unrelated schizophrenic patients (175 males
and 69 females) and 210 controls (131 males and 79 females) were recruited
from the north and center of Portugal-mainland. The Brazilian sample con-
sisted of 69 cases and 85 controls, all unrelated males living in the area of
Porto Alegre. A third, independent sample composed of 73 patients (47 males
and 26 females) and their parents from the Azorean Islands (Portugal), was
used for family-based association analysis. All subjects were of European an-
cestry. All participants gave informed consent for genetic studies and ethic
committees of the institutions involved approved the study.
All patients from Portugal-mainland and Azorean Islands, as well as 45%
of Portugal-mainland controls and 67% of the Azorean parents were evalu-
ated using the Diagnostic Interview for Genetic Studies (DIGS) [283], a semi-
structured interview that assesses the criteria for schizophrenia and other psy-
chiatric diseases. The diagnosis was made based on the Diagnostic and Sta-
tistical Manual of Mental Disorders, review of the third edition (DSM-IIIR) [11].
All Brazilian patients were classified using the Operational Checklist for Psy-
chotic Disorders (OPCRIT) [237]. No psychological assessment interviews
have been conducted in the remaining Portuguese mainland controls (stu-
dents and organ donors) or Azorean parents, or in any of the Brazilian controls
(blood donors).
5.2.2 Polymorphism screening
Using single strand conformational polymorphism (SSCP) analysis, a sub-
sample of 60 patients from the Portuguese mainland was used for screening
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variants in all four exons and adjacent splicing sites, as well as the promoter
and the 3´ untranslated regions. For this analysis the PCR products were sub-
jected to electrophoresis on a non-denaturing polyacrylamide gel under two
temperature conditions: 4oC and 25oC. After completion of the electrophore-
sis, band patterns were visualized with silver staining, using standard pro-
tocols. PCR products from subjects displaying altered band patterns in the
SSCP analyses were sequenced in both directions. The sequencing reactions
were performed using the BigDye Sequencing Kit 3.1 and run on the 3700
sequencer, both from Applied Biosystems (Foster City, CA).
The TTR sequence was obtained from the GenBank Data Libraries (acces-
sion no. M11844) and the Primer3 program [319] was used for primer design.
Primer sequences are available upon request.
5.2.3 SNP genotyping
Two single nucleotide polymorphisms (SNP) were detected: rs1800458 on
exon 2 and ss46566417 on intron 3 (Figure 5.1). These two SNPs were further
typed for association in the complete samples described above.
Detection of rs1800458 and ss46566417 was based upon analysis of primer
extension products generated from previously amplified genomic DNA, using a
chip-based MALDI-TOF mass spectrometry platform (SEQUENOM Inc., San
Diego, CA). PCR primers with a universal (10 bp) sequence at the 5´ end
(5´- ACGTTGGATG-3´) and the extension primer were created using the Mas-
sARRAY Assay Design 2.0 software (SEQUENOM), following manufacturer’s
instructions. For the MALDI-TOF analysis, aliquots of the samples were spot-
ted onto a SpectroCHIP (SEQUENOM). Mass spectra were generated by the
MassARRAY spectrometer (SEQUENOM). Genotypes were automatically de-
termined using the SpectroTYPER software (SEQUENOM). In some cases
genotyping of rs1800458 was repeated using PCR-based restriction fragment
length polymorphism assay. The same PCR product used for the SSCP anal-
ysis was digested with the endonuclease Cfr 10I (Fermentas, Vilnius, Lithua-
nia). The digested reactions were resolved by electrophoresis on 3% agarose
gels.
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5.2.4 Measurement of TTR and RBP serum levels
Twenty six schizophrenic patients (16 males and 10 females) and 54 con-
trols (25 males and 29 females) from Portugal-mainland as well as 27 schizo-
phrenic patients (15 males and 12 females) from the Azorean Islands were
used to measure the serum levels of TTR, RBP, and albumin. Serum TTR,
RBP, and albumin were determined by radial-immunodiffusion in accordance
to the manufacturer’s instructions (The Binding Site Limited, Birmingham, UK).
5.2.5 Statistical analysis
The genotype and allele frequencies were compared between cases and con-
trols using a standard χ2 test, calculated by SPSS (version 13.0). Hardy-
Weinberg Equilibrium (HWE) was assessed in the same way.
To analyze the results of the family-based association study (Azorean sam-
ple), a transmission disequilibrium test (TDT) was performed, using TRANS-
MIT version 2.5.4 [67].
Student’s t-test was used to compare ages and protein serum levels be-
tween patients and controls. Association between serum TTR, RBP and al-
bumin levels and their correlation with age was analyzed by linear regression.
These last two analyses were also performed with SPSS. For all tests, the
results were considered significant when the P-value was less then 5%.
5.3 Results
5.3.1 Association study
In the 60 patients screened for variants we detected the presence of two SNPs:
the previously described rs1800458 on exon 2 and the novel ss46566417,
18bp upstream from exon 4 (Figure 5.1). The novel SNP has been submitted
to the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/).
HWE was verified for all tested samples, showing no deviation for either
SNP analyzed (Table 5.1). Table 5.1 summarizes the genotyping results for
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Figure 5.1: Genomic structure of human TTR gene and locations of the two SNPs analyzed.
Black boxes represent protein-coding regions, white boxes represent untranslated regions.
Locations of initiation (ATG) and stop (TGA) codons and sizes of introns and exons are also
provided. The rs and ss numbers identify the SNPs according with the dbSNP database of
NCBI (http://www.ncbi.nlm.nih.gov/SNP/).
Table 5.1: Case-Control analyses for the two SNPs studied
Origin SNP (phenotype) Genotype (frequencies) P-value HWE
Portugal rs1800458 GG GA AA
mainland Cases (n=163) 0.914 0.086 0.000 0.496 0.567
Controls (n=161) 0.888 0.106 0.006 0.533
ss46566417 GG GC CC
Cases (n=244) 0.906 0.094 0.000 0.513 0.440
Controls (n=209) 0.890 0.105 0.005 0.691
Brazil rs1800458 GG GA AA
Cases (n=69) 0.855 0.145 0.000 0.617 0.516
Controls (n=85) 0.882 0.118 0.000 0.564
ss46566417 GG GC CC
Cases (n=69) 0.928 0.072 0.000 0.964 0.755
Controls (n=85) 0.929 0.071 0.000 0.736
Represented are the genotype frequencies, P-values and HWE values.
the two SNPs. No significant differences between cases and controls were
detected in genotype or allele frequencies, either in the Portuguese mainland
or in the Brazilian samples. The lack of association was confirmed in the
Azorean sample, since the TDT revealed no excess of transmission from par-
ents to offspring (Table 5.2).
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Table 5.2: Individual SNP analysis by TRANSMIT.
SNPs major>minor allele (frequencya) χ2 (df=1) P-value
rs1800458 G>A (0.034) 0.517 0.472
ss46566417 G>C (0.045) 0.077 0.782
aFrequency of the minor allele, produced by the TRANSMIT program.
5.3.2 TTR, RBP and albumin serum levels
Serum levels of TTR, RBP and albumin did not differ between schizophrenic
and mentally healthy individuals, whether male or female. There were no sta-
tistical differences of TTR, RBP or albumin serum levels between the analyzed
Portuguese mainland and Azorean patients. Therefore these values are pre-
sented together in Table 5.3. Distribution of age in the sample used was not
well matched between patients and controls (Table 5.3). However, within this
age-range, age did not influence the levels of TTR, RBP and albumin, as ver-
ified by linear regression analysis (P-value=0.176 for TTR, P-value=0.330 for
RBP and P-value=0.736 for albumin). As expected, TTR and RBP levels were
positively correlated, when analyzed by linear regression (P-value<0.0005).
5.4 Discussion
In the present study we describe a novel TTR polymorphism, ss46566417
with an allele frequency of 0.048 in Caucasians [0.052 (47/906) in Portuguese
from mainland, 0.048 (14/292) in Azorean, and 0.036 (11/308) in Brazilian].
This novel polymorphism does not change the amino-acid sequence of the
protein, since it is localized on intron 3, but might interfere with transcrip-
tion given its close proximity to a splicing site. We also detected the SNP
rs1800458 at an allele frequency (0.059) similar to that previously described
in the Caucasian population [172]. Neither of these two SNPs was found as-
sociated with schizophrenia. While the present study, as many others, failed
to identify genetic variants that predispose to schizophrenia, recent studies in
brains from schizophrenic patients have shown altered expression of several
5.4 Discussion 69
Table 5.3: TTR, RBP and albumin serum levels in patients and in controls.
Males P-value Females P-value
Cases Controls Cases Controls
N 31 25 22 29
Age 36.6±15.0 29.7±6.8 0.028 42.2±11.4 31.6±9.9 0.001
TTR (mg/L) 296.9±49.4 295.4±34.6 0.898 277.0±51.1 284.3±49.5 0.610
RBP (mg/L) 67.8±16.3 65.4±9.9 0.495 64.9±13.9 61.8±13.4 0.427
Albumin (mg/L) 42832±5585 43940±5789 0.473 41027±4385 41183±4900 0.906
Data represented as means±SD.
genes [134, 252]. Such alterations might result from variants in the regulatory
regions of the genes but also from inadequate availability of transcription mod-
ulators such as hormones and vitamins [293]. For these reasons, and even
though we failed to detect association of the TTR polymorphisms with schizo-
phrenia, in these two populations, we investigated the circulating levels of TTR
and also of RBP. Serum levels of RBP did not differ between schizophrenic and
mentally healthy individuals. Being the only plasma carrier for retinol, RBP is
measured as a surrogate marker of retinol in the circulation [70]. Therefore,
our data suggest that serum retinoid status is not altered in patients diag-
nosed with schizophrenia, since retinol is the most common form of retinoids
in circulation. This is, however, in contrast with another study in which the
serum levels of RBP and other inflammatory acute phase proteins such as al-
bumin were found decreased in the serum of Chinese schizophrenic patients
from Singapore [409]. Given that our patient sample showed normal albumin
serum levels, and since RBP is a useful marker of protein malnutrition [70] and
of inflammatory acute phase response [103], it is possible that the values ob-
served in that study might reflect a particular nutritional or inflammatory state
in the patients. While we found no changes in RBP circulating levels in our
patient population, search for RBP variants should be investigated since these
could impair the ability to carry retinol and/or to bind to TTR.
Ours is the first report on serum levels of TTR and we found no differences
between schizophrenic and control individuals. It should be noted that serum
TTR levels do not necessarily reflect CSF levels since the first is mainly de-
rived form the liver while the latter is primarily synthesized and secreted from
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the choroid plexus [9]. In fact, TTR expression has been described as dif-
ferentially regulated in the liver and in the choroid plexus [80]; probably due
to the presence of tissue specific transcription factors. Recent interest in the
possible decrease of CSF TTR during aging has been raised mainly in the
context of Alzheimer’s disease, since TTR is also able to bind the Alzheimer
β peptide [54]. It would therefore be interesting to measure CSF TTR levels
in patients, where available, to extend a single study in which CSF TTR levels
were reported normal in patients with schizophrenia [34]. All together the data
obtained to date does not support the involvement of TTR in the pathophys-
iology of schizophrenia. However, it is important to investigate whether TTR
polymorphisms are related to any particular symptom or response to medica-
tion, or whether the levels of TTR ligands, rather then TTR itself, are involved
in the etiology of schizophrenia.
6
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Abstract
The neurogranin (NRGN) gene produces a postsynaptic brain-specific
protein that regulates calmodulin-Ca2+ availability in neurons. Acting
downstream of the NMDA-receptor and upstream of calcineurin and other
proteins implicated in schizophrenia, NRGN is a good candidate for as-
sociation studies in schizophrenia. NRGN expression is regulated dur-
ing development and is modulated by thyroid hormones and retinoids,
molecules essential for the proper development of the central nervous
system. Given the genetic complexity of schizophrenia and the poten-
tial genetic heterogeneity in different populations, we studied a possi-
ble association of NRGN with schizophrenia in 73 Azorean proband-
parent triads and in two independent case-control samples from the
Portuguese mainland (244 schizophrenic and 210 controls) and Brazil
(69 schizophrenic and 85 mentally healthy individuals). Genotype dis-
tribution showed association of the rs7113041 SNP with schizophrenia
in males of Portuguese origin, which was confirmed by the analysis of
the proband-parent triads. This evidence, implicating NRGN in schizo-
phrenia, introduces another player into the glutamatergic hypothesis of
schizophrenia.
6.1 Introduction
Family, twin, and adoption studies clearly indicate a genetic contribution to the
etiology of schizophrenia [238, 239]. The frequent discordance of monozy-
gotic twins in developing schizophrenia, suggests that environmental factors
are also involved in disease manifestation [126]. The disease is proposed to
result from a neurodevelopmental impairment occurring during gestation that
is caused by a combination of genetic and environmental factors [372]. Age of
onset ranges from mid to late adolescence through early adulthood, affecting
males more often and more severely than females [279, 10].
Despite the family aggregation of schizophrenia, linkage studies have failed
to identify a major risk chromosomal region [301], which suggests the involve-
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ment of multiple genes each conferring a minor increase in disorder suscep-
tibility [347]. The idea of a polygenic origin of the disease is reinforced by
studies in schizophrenia postmortem brains revealing altered expression of
several genes and proteins [134, 252]. Altered expression of genes could re-
sult either from polymorphisms in their regulatory regions, e.g. the promoter,
or from inadequate supply of modulators of transcription activity [280]. Accord-
ingly, it has been suggested that modulators, such as hormones and vitamins,
are a possible link between the genetic and environmental components of the
complex schizophrenia disorder [125, 293].
Thyroid hormones and retinoids are essential for the normal mammalian
brain development [221, 268]. They regulate processes such as differentia-
tion of the cerebellum, axonal migration and myelination [317], and the con-
trol of lateralization and symmetry of the embryo [383, 382]; processes that
have been implicated in schizophrenia [293]. Their mechanism of action is
mainly through the regulation of transcription of genes including those encod-
ing myelin basic protein [317], dopamine receptor D2 [327] and the receptor for
neuregulin1, ERBB4 [285]; all genes previously implicated in schizophrenia.
Among the genes whose expression is regulated by thyroid hormones and
retinoids is the neurogranin (NRGN) gene [93, 130, 161, 165] that encodes
a postsynaptic brain-specific protein. The human NRGN gene, localized on
chromosome 11q24.2 [228], consists of four exons and three introns. The 78-
amino-acid protein is encoded by part of exon 1 and by exon 2 [228] and a
thyroid hormone response element (TRE) has been identified in intron 1 [227].
Information on the function of NRGN stems from studies in rodents. NRGN
accumulates in dendritic spines of specific neurons within the cerebral cortex,
hippocampus, striatum, and amygdala [276, 394]. During development, NRGN
expression is regulated by maternal thyroid hormones [81] and its highest ex-
pression is coincident with the development period characterized by rapid den-
dritic growth and formation of the majority of the cortical synapses [165]. Of
particular relevance is the fact that NRGN binds calmodulin (CaM) with high
affinity [108, 300, 303], buffering postsynaptic CaM levels and modulating the
concentration of Ca2+ in neurons [157]. Phosphorylation by protein kinase C
(PKC) or oxidation by nitric oxide decreases CaM-binding affinity [156, 211].
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Glutamate stimulation of N-methyl-D-aspartate (NMDA) receptors results in
Ca2+ influx to the neuron and in NRGN oxidation [211]. These induce dis-
sociation of the NRGN-CaM complex and stimulate the phosphorylation of
NRGN by PKC [318], which prevents the re-binding of NRGN and CaM. As
a CaM reservoir, NRGN regulates the release of CaM and the activities of
downstream CaM-Ca2+-dependent enzymes that play an important role in the
neuroplasticity mechanisms of learning and memory [157, 291]. Therefore,
altered NRGN activity could mediate the effects of NMDA receptor hypofunc-
tion suggested by several studies to be implicated in the pathophysiology of
schizophrenia [368]. These observations prompted us to investigate NRGN
as a candidate gene in schizophrenia.
Case-control studies compare allele and genotype distributions between
affected and unaffected individuals. When a significant result is obtained, it
may be due to linkage between the marker and the disease but can as well
reflect population stratification. Family-based association analysis compares
the allele and genotype frequencies between cases and their parents to ex-
plore if a specific marker is transmitted to a greater degree than expected
under Mendelian inheritance. This analysis is robust against possible popula-
tion stratification. Therefore, we decided to conduct the association study of
NRGN using both case-control samples (from Portugal-mainland and Brazil)
and family-based samples (from Azorean Islands).
6.2 Materials and methods
6.2.1 Samples
Two case-control samples were used: one from Portugal and one from Brazil.
The Portuguese sample consisted of 244 cases (175 males and 69 females)
and 210 unrelated controls (131 males and 79 females), recruited from the
north and center of the Portuguese mainland. Patients with clinical diagno-
sis of schizophrenia were systematically drawn from both the inpatient and
outpatient clinic at the University Hospital of Coimbra. The Brazilian sample
consisted of 69 cases and 85 controls, all unrelated males living in the area
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of Porto Alegre. All Brazilian patients were under outpatient care. A third, in-
dependent sample consisting of 73 patients (48 males and 25 females) and
their parents from the Azorean Islands, was used for family-based association
analysis. Based on the individuals’ report of their parents’ ethnicity, on family
history, and on the observation of skin, facial and hair characteristics, all sub-
jects were classified as Caucasians. The Porto Alegre region, in the south-
ern part of Brazil, is considered to have 92% of European ancestry, mostly
Portuguese, Spanish, German and Italian [105, 331]. All participants gave
informed consent for genetic studies, and ethic committees of the institutions
involved approved the study.
All patients from Portugal-mainland and Azorean Islands, as well as 45%
of Portugal-mainland controls and 67% of the Azorean parents were evaluated
using the Portuguese version of the Diagnostic Interview for Genetic Studies
(DIGS) [283], a semi-structured interview that assesses the criteria for schizo-
phrenia and other psychiatric diseases. The diagnosis was made based on
the Diagnostic and Statistical Manual of Mental Disorders, review of the third
edition (DSM-IIIR) [11]. All Brazilian patients were classified using the Oper-
ational Checklist for Psychotic Disorders (OPCRIT) [21, 237]. No psychologi-
cal assessment interviews have been conducted in the remaining Portuguese
mainland controls (students and tissue donors) or Azorean parents or in any
of the Brazilian controls (blood donors).
For 97% of the Portuguese mainland, 44% of the Azorean and 87% of the
Brazilian patients, information on age of onset, based on the OPCRIT criteria,
was available. Specifically, for males, it was 22 ± 6 (n=171), 20 ± 4 (n=21),
and 20 ± 5 (n=60), respectively; and for females, 22 ± 6 (n=66) and 26 ± 7
(n=11). Please note that the Brazilian sample is all males.
Blood was drawn from all subjects and DNA extracted using standard
salting-out procedures.
6.2.2 Polymorphism screening
Using Single Strand Conformational Polymorphism (SSCP) analysis, a sub-
sample of 60 patients from the Portuguese mainland was used for screening
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Figure 6.1: Genomic structure of the human NRGN gene and positions of the three SNPs
tested and of the mutation found. Black boxes represent protein-coding regions, white boxes
represent untranslated regions, and the grey line represents the thyroid hormone response
element (TRE). Locations of initiation (ATG) and stop (TAG) codons, sizes of introns and
exons, and physical distances between markers are also shown. The rs numbers identifying
the SNPs are in accordance with the dbSNP database
DNA variants in the four exons and adjacent splicing sites, as well as in the
thyroid hormone response element (TRE) on intron 1 of the NRGN gene. For
this analysis the PCR products were subjected to electrophoresis on a non-
denaturing polyacrylamide gel under two temperature conditions: 4oC and
25oC. After completion of the electrophoresis, PCR products were visualized
with silver staining. PCR products from subjects displaying altered band pat-
terns in the SSCP analyses were sequenced in both directions. The sequenc-
ing reactions were performed using BigDye Sequencing Kit 3.1 and run on a
3700 sequencer, both from Applied Biosystems (Foster City, CA).
The NRGN sequence was obtained from the GenBank Data Libraries (ac-
cession no. AJ317956), and the Primer3 program [319] was used for primer
design. Primer sequences are available upon request.
6.2.3 SNP genotyping
Three previously described single nucleotide polymorphisms (SNPs) were geno-
typed: rs7113041 in intron 1, rs1804829 in exon 4, and rs12541 localized
downstream of the exon 4 (Figure 6.1).
Specifically, rs12541 was genotyped using a PCR-based restriction frag-
ment length polymorphism (RFLP) assay. The PCR product was submitted
to digestion using Bfm I endonuclease (Fermentas, Vilnius, Lithuania). The
digested reactions were resolved by electrophoresis on agarose gel.
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Detection of SNPs rs7113041 and rs1804829 was based upon analysis of
primer extension products generated from previously amplified genomic DNA,
using a chip-based MALDI-TOF mass spectrometry platform (Sequenom Inc.,
San Diego, CA). PCR primers with a universal (10 bp) sequence at the 5´ end
(5´-ACGTTGGATG-3´) and the extension primers were created using the Mas-
sARRAY Assay Design 2.0 software (Sequenom), following manufacturer’s in-
structions. For the MALDI-TOF analysis, aliquots of the samples were spot-
ted onto a SpectroCHIP (Sequenom). Mass spectra were generated by the
MassARRAY spectrometer (Sequenom). Genotypes were automatically de-
termined using the SpectroTYPER software (Sequenom).
6.2.4 Statistical analysis
Student’s t-test was used to compare age distributions between patients and
controls. Hardy-Weinberg equilibrium and gender distribution were assessed
using Chi-square (χ2) test.
Linkage disequilibrium (LD) between pairs of loci was evaluated by r 2. The
r 2 measure represents the statistical correlation between two sites and takes
the value of 1 if only two haplotypes are present. There is a simple inverse
relationship between r 2 and the sample size required to detect association
between susceptibility loci and SNPs [387]. The r 2 values were computed
using the ldmax program from the GOLD software package [2].
Global genotypic distributions (2 × N contingency tables) were compared
between patients and controls by χ2 test. Allele and specific genotype frequen-
cies (2× 2 contingency tables) were compared between these two groups by
Fisher’s exact test, instead of the χ2test. Fisher’s exact test is the usual choice
for testing the significance in association studies and it is believed to be the
most reliable test when one or more of the expected numbers in the 2×2 table
is less than five, and when the overall sample size is small [177]. Confirmation
of the case-control results was done in the family-based sample by evaluating
transmission distortions using pedigree disequilibrium test (geno-PDT) [226].
Genotype frequencies among controls from Portugal-mainland and Brazil,
and between these two groups and the genotypes made of non-transmitted
78 NRGN and schizophrenia 6
alleles in the trios sample were compared using χ2 test. This was done both
for the overall samples and for the male subsamples. The same test was used
for comparing genotype frequencies among cases from different origins and
in overall and male subsamples. χ2 test, Fisher’s exact test, P-value, and
Odds Ratios (ORs) and the 95% confidence intervals (CI) were computed by
InStat 3.06 (GraphPad Software). All tests were two-tailed and results were
considered to be significant if the P-value was less than 5%.
6.3 Results
By SSCP, a new single nucleotide variant (c.-71C>T on exon 1) [mutations
nomenclature follow recommendation by Antonarakis [15]] and two previously
described SNPs (rs7113041 in intron 1 and rs1804829 in exon 4) were iden-
tified (Figure 6.1). These SNPs together with a third SNP (rs12541 located
downstream the gene) obtained from the NCBI SNP database, were further
genotyped in the complete samples described in subsection 2.1. The c.-
71C>T variant was found in one heterozygous out of 60 cases screened, and
was not used in the association study given its low frequency.
Analysis of gender distribution in the Portuguese mainland sample showed
that males have significantly (P-value=0.034) higher relative frequency in cases
(71.7%) than in controls (62.4%). Distribution of age was well matched be-
tween patients and controls for both Portuguese mainland and Brazilian sam-
ples (P-value>0.4 for both samples). The same was true after the Portuguese
mainland sample was stratified by gender (P-value=0.232 for males and P-
value=0.443 for females).
Pairwise LD was calculated between the three SNPs in the two case-
control samples and in the 146 unrelated parents (See Table 6.1). We de-
tected a weak but significant LD between rs7113041 and rs12541 in the three
samples (r 2 >0.1 and P-values<0.001 for all samples). This result is concor-
dant with the HapMap data. The P-values obtained for the LD analysis of the
SNPs rs7113041 and rs1804829 are not significant (P-value>0.05) and thus
we can not conclude on linkage disequilibrium between them. In this case, it
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Table 6.1: Linkage disequilibrium, measured by r2, between the polymorphic loci for all
samples studied.
Combination Portuguese mainland Brazil Azorean parents
rs7113041-rs1804829
r 2 (P-value) 0.005 (0.097) 0.020 (0.096) 0.009 (0.083)
rs7113041-rs12541
r 2 (P-value) 0.135 (0.000) 0.313 (0.000) 0.138 (0.000)
rs1804829-rs12541
r 2 (P-value) 0.011 (0.002) 0.012 (0.307) 0.008 (0.258)
appears that the minor allele of one SNP is in linkage disequilibrium with the
major allele of the other SNP, a scenario under which large sample sizes are
needed to obtain significance. The SNPs rs1804829 and rs12541 were found
not to be in LD in the largest sample (Portuguese-mainland, P-value=0.002,
r 2=0.011.). However, though on average LD decreases with physical distance,
that does not always occur [3].
In view of the gender mismatch in the Portuguese mainland sample, this
sample was stratified by gender (note that the Brazilian sample is composed
of males only). After gender stratification, we found a significant excess of
the CG genotype at the rs7113041 marker in males (Table 6.2). In this case-
control sub-sample, the frequency of rs7113041-CG was 43.4% in patients
and 30.3% in controls, with this genotype predisposing males to develop the
disease (OR=1.764; CI=1.082 to 2.874). In the same way, though reach-
ing marginal significance only (Table 6.2), the Brazilian case-control sample
showed an excess of rs7113041 heterozygous in patients (53.0%) when com-
pared with controls (36.7%), with this genotype also increasing the predis-
position to the disease (OR=1.947; CI=1.000 to 3.788). In both case-control
samples, no differences between cases and controls were found in the geno-
type distribution of the other two markers, rs1804829 and rs12541, nor in the
allelic distribution of any of the three SNPs.
In the sample of the 73 Azorean parents-offspring, no transmission distor-
tion of alleles was found for any of the three SNPs analyzed. However, using
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Table 6.2: Genotype distributions at marker rs7113041.
Sample Total sample P-valueb Male P-valueb Female P-valueb
origin Case Control Case Control Case Control
Portugal mainland
CC 131 (53.7) 113 (57.4) 0.500 92 (52.6) 76 (62.3) 0.122 39 (56.5) 37 (49.3) 0.408
CG 103 (42.2) 71 (36.0) 0.203 76 (43.4) 37 (30.3) 0.029 27 (39.1) 34 (45.3) 0.502
GG 10 (4.1) 13 (6.6) 0.284 7 (4.0) 9 (7.4) 0.296 3 (4.3) 4 (5.3) 1.000
Total 244 197 0.269 175 122 0.051 69 75 0.687
Brazil
CC 30 (45.5) 44 (55.7) 0.246
CG 35 (53.0) 29 (36.7) 0.065
GG 1 (1.5) 6 (7.6) 0.127
Total 66 79 0.059
Combined samplea
CC 196 (51.6) 194 (56.1) 0.234 146 (50.9) 141 (57.1) 0.164 50 (53.8) 53 (53.5) 0.642
CG 172 (45.3) 126 (36.4) 0.016 133 (46.3) 85 (34.4) 0.006 39 (41.9) 41 (41.4) 0.754
GG 12 (3.2) 26 (7.5) 0.012 8 (2.8) 21 (8.5) 0.004 4 (4.3) 5 (5.1) 1.000
Total 380 346 0.005 287 247 0.001 93 99 0.970
aCombined sample also includes transmitted and non-transmitted genotypes from Azores.
bP-value was assessed using Fisher’s exact test with the exception of the global P-value that
was obtained by χ2 test with 2df. Fisher’s exact test were derived from a series of simple 2×2
tables based on the frequency of each genotype versus all others combined between the case
and control groups. P-values<0.05 are shown in bold.
geno-PDT, which allows the detection of interaction between alleles at a single
locus, we found a significant under-transmission (P-value=0.034) of the geno-
type GG at the marker rs7113041 (Table 6.3). After stratifying probands by
gender, the transmission deficit of the GG genotype was maintained for males
(P-value=0.014) but not for females (Table 6.3).
In order to increase the power of the rs7113041 analysis, we pooled the
cases from the three different samples and pooled the controls from Portugal-
mainland and Brazil with the genotypes made of non-transmitted alleles from
the Azorean triads (Table 6.2). Such pooling can be justified because all three
independent samples have a common European origin and because no differ-
ence was found when genotype frequencies of cases or controls were com-
pared between the three samples. In this combined analysis, the genotype
distribution showed significant differences between schizophrenic patients and
controls in males, but again this difference was not detected in females. Specif-
ically, the CG association found in males from Portuguese-mainland and the
GG association found in the Azorean male offspring were both present in the
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Table 6.3: Transmission of marker rs7113041 in Azorean triads with schizophrenia.
Mating Total sample (n=70) Male Offspring (n=46) Female Offspring (n=24)
Type CC CG GG CC CG GG CC CG GG
CC×CC 16 - - 10 - - 6 - -
CC×CG 14 20 - 9 11 - 5 9 -
CC×GG - 6 - - 4 - - 2 -
CG×CG 5 6 1 5 6 0 0 0 1
CG×GG - 2 0 - 1 0 - 1 0
GG×GG - - 0 - - 0 - - 0
n (%) 35 (50.0) 34 (48.6) 1 (1.4) 24 (52.2) 22 (47.8) 0 (0.0) 11 (45.8) 12 (50.0) 1 (4.2)
TDT 35 T/37 NT 34 T/26 NT 1 T/7 NT 24 T/21 NT 22 T/19 NT 0 T/6 NT 11 T/16 NT 12 T/7 NT 1 T/1 NT
P-valuea 0.752 0.182 0.034 0.549 0.513 0.014 0.197 0.197 1.000
aP-values were obtained by Geno-PDT program; T=Transmitted; NT=Non-transmitted.
combined male sample (Table 6.2). In this combined sample, the CG genotype
was found to be over-represented in male patients (P-value=0.006; OR=1.65;
CI=1.16 to 2.34), while the GG genotype was more frequent in male controls
(P-value=0.004; OR=0.31; CI=0.13 to 0.71). In the same way when the ef-
fect of CC+CG together was analyzed against GG, a predisposition to develop
schizophrenia was observed (P-value=0.004; OR=3.24; CI=1.41 to 7.46). Al-
lelic distribution remained not associated.
The haplotype analysis of the two markers in linkage disequilibrium (i.e.,
rs7113041-rs12541) did not show genetic association with schizophrenia when
overall frequencies were compared in any of the three samples analysed. Al-
though we found association of specific classes of geno-haplotypes and hap-
lotypes after gender stratification, the obtained results were not more informa-
tive than the ones reported in the genotypic analysis (P-values>0.028). These
additional results are available upon request.
Hardy-Weinberg equilibrium was determined for the three SNPs tested in
the three samples analyzed, and no deviation was found in controls, parents
or overall groups. A deviation was found in the male patients from Brazil and
Azores, and a borderline P-value was found in males from Portugal-mainland,
which could in fact be a result of the association we described above [407].
6.4 Discussion
To date, the chromosomal region in which the NRGN gene is located has been
implicated in schizophrenia by a single genome-wide linkage study [132]. The
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present study provides evidence implicating the NRGN gene itself in schizo-
phrenia. Specifically, the rs7113041-CG genotype showed significant differ-
ences between male patients and male controls in the Portuguese-mainland
sample, with this genotype predisposing to the disease. The Brazilian sample
shows the same tendency. Since population admixture is a legitimate concern
for positive findings in case-control association studies [79], we performed a
family-based association study on an independent sample from the Azorean
Islands, and a deficit of transmission of the rs7113041-GG genotype from par-
ents to the affected male offspring was detected. In accordance with the
results of the case-control analysis, no transmission distortion was detected
to female offspring. Interestingly, the GG genotype seems protective against
schizophrenia in the Azorean sample. The same tendency is observed in both
case-control samples, even though not reaching statistical significance. This
might be related to the sample size since in the combined analysis (all samples
included) we did detect a significant association of the GG genotype.
We tested 3 SNPs located in the NRGN gene in two case-control sam-
ples plus one parents-offspring sample. This procedure amounts to multiple
testing, and formally P-value correction needs to be applied. However, the
appropriate method of correction for multiple comparisons in candidate gene
association studies remains unclear [343]. Nevertheless, the fact that we find
a nominally significant (at P-value<0.05) association of rs7113041 CG and
GG genotypes in two independently ascertained populations (males from the
Portuguese-mainland and in the Azorean male-offspring), and highly signifi-
cant (P-value=0.001) association in the pooled male sample, gives us confi-
dence in our finding.
Particularly intriguing is the fact that we found a gender related associa-
tion in both family-based and case-control samples, which may be related to
phenotypic sex differences observed in schizophrenia. It is known that schizo-
phrenia presents a gender bias in age of onset, severity, clinical course, and
response to antipsychotic drugs [10, 208], and that some neuroanatomical
changes in schizophrenia are sex-dependent [149]. However, to our knowl-
edge, NRGN has never been reported to mediate such phenotypic differences.
Larger samples and stratification by several disease features will be needed
6.4 Discussion 83
to establish whether the association is in fact due to gender or to some spe-
cific symptom mediated by NRGN that is more frequent in males. The gen-
der bias we found is not unprecedented, since other schizophrenia studies
also identified gender-specific effects on genes such as DISC1, ZDHHC8, and
COMT [145, 273, 342].
The implicated SNP rs7113041 is located in a noncoding region, but be-
cause it is in the vicinity of the TRE it can interfere with the binding of the
thyroid hormone receptor and subsequently influence the transcription of the
NRGN gene. Functional assays will be needed to analyze the impact of the
rs7113041 polymorphism on the NRGN expression. Of relevance is the recent
finding of decreased NRGN protein levels in the prefrontal cortex of schizo-
phrenic patients [40]. Since 6 out of the 7 brains used in that study are from
males, it will be of interest to verify whether the rs7113041 genotype of those
individuals relates with the altered protein levels reported.
NRGN is a new player in the glutamatergic hypothesis of schizophrenia.
Several initial clinical observations support that the pathophysiology of schizo-
phrenia involves an NMDA receptor hypofunction [368]. NMDA receptor an-
tagonists, such as phencyclidine (PCP), ketamine, and MK-801, mimic schizo-
phrenia in healthy individuals [191] or exacerbate symptoms in schizophrenic
patients [193]. Moreover, treatment with the atypical antipsychotic clozapine
attenuates exacerbation of clinical symptoms produced by ketamine [222].
Similarly, schizophrenia-like behavior in mice with reduced levels of NMDA
receptor expression (5% of the normal level) can be reverted in part by the
administration of antipsychotic drugs [259]. In addition, agents that act as
agonists at the glycine modulator site on the NMDA receptors improve nega-
tive symptoms and have a variable effect on cognitive and positive symptoms
in schizophrenic patients [369]. Interestingly, kynurenic acid, an endogenous
antagonist of NMDA receptor, has been reported to be increased in the hip-
pocampus of schizophrenics in postmortem studies [334].
Analysis of the glutamatergic transmission places NRGN in the center of
the glutamatergic pathway. Figure 6.2 summarizes the relationship of NRGN
with the glutamatergic hypothesis of schizophrenia. On one hand, NRGN is
a downstream target of glutamatergic transmission. Thus the hypofunction of
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Figure 6.2: Summary of the relationship of NRGN with the glutamatergic hypothesis of
schizophrenia
the NMDA receptor present in schizophrenia will impair NRGN phosphoryla-
tion/oxidation. On the other hand, by regulation of intracellular levels of Ca2+
and CaM-Ca2+, disruption of NRGN homeostasis will alter postsynaptic signal
transduction pathways, which are regulated by these secondary messengers.
Interestingly, schizophrenic postmortem brains have altered expression levels
of CaM-Ca2+ target genes. While PKC [71], calcineurin [87] and 14-3-3 [249]
were found decreased in the temporal lobe, hippocampus, and prefrontal cor-
tex, respectively, CaMKII levels were found increased in the prefrontal cor-
tex of schizophrenic brains [281]. This can be a consequence not only of
the NMDA receptor hypofunction but also of the reduced NRGN levels [40].
Altered NRGN activity could ultimately result in the dendritic and spine loss
described in schizophrenia [39, 111, 118] as suggested by Broadbelt and col-
laborators [40].
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An interesting feature in the relation between glutamatergic neurotransmis-
sion and schizophrenia, that can be explained at least in part by NRGN func-
tion, is the observation that the psychotomimetic effects of NMDA antagonists
are minimal or absent in children but become apparent in late adolescence
and early adulthood [402], the time when schizophrenia symptoms typically
have their onset. This could reflect a direct influence of hormonal status in
the NMDA receptor or in any of its downstream effectors, like NRGN which is
supported by the age-related down-regulation of NRGN expression observed
in rodents [99, 266]. In addition, several modulators of NMDA receptor activity,
implicated in schizophrenia, could exert their effect, at least in part, by altering
NRGN activity. Among these are dysbindin, neuregulin, D-amino acid oxidase
activator (DAOA), and regulator of G-protein signaling 4 (RGS4), all strong
candidates in the pathophysiology of schizophrenia [142].
In conclusion, we have found an association of theNRGN gene with schizo-
phrenia in males. Given NRGN’s known functions, one may speculate that it
plays a role specifically in the cognitive deficits observed in the disease. Future
work needs to clarify the significance of this association.
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7
Thyroid hormone function in
schizophrenia - a preliminary
study
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Abstract
Several lines of evidence support that schizophrenia arises from the cu-
mulative effect of many risk factors that in combination disrupt the normal
brain development. Both genetic and environmental factors are believed
to interplay in the etiology of schizophrenia.
Given the importance of thyroid hormones in the normal development
of the central nervous system, it has been suggested that abnormal lev-
els of this hormone, during critical periods of brain development, could
explain the deviations from normal neurodevelopmental found in schizo-
phrenic patients.
Even though the thyroid hormone levels in adults will not necessary
reflect the values present during embryonic development they may pro-
vide an indication. In the present study we investigate the serum levels
of thyroid hormones in schizophrenic male patients and compare them
with mentally healthy individuals. The levels of triiodothyronine (T3) in its
free form were found significantly decreased in schizophrenic male pa-
tients. We also observed higher prevalence of thyroid disorders among
mothers of patients. Together, these two preliminary observations sug-
gest that patients may have been exposed to TH deficiency during gesta-
tion, which, if confirmed, reinforces the neurodevelopmental hypothesis
of schizophrenia.
When comparing stable patients with patients in crisis, the levels of
total T3 were found decreased in the latter. Since both groups are un-
der medication, this decrease may be associated to manifestation of a
particular symptom, which should be further investigated.
7.1 Introduction
Schizophrenia is a disabling mental disorder that affects about 1% of the popu-
lation worldwide [171]. Schizophrenic patients present brain abnormalities that
are likely to have a neurodevelopmental origin [225]. Epidemiological studies
clearly indicate that genetic factors play an important role in the etiology of
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schizophrenia [239], and that these might interplay with environmental risk
factors to lead to disease onset [68, 42, 358, 154].
Recent findings suggest that prenatal nutritional deprivation may be an en-
vironmental risk factor for schizophrenia [350, 358], although it is not known
whether the predisposition increases due to general malnutrition or lack of a
specific micronutrient. Among the essential micronutrients is iodine, whose
dietary intake is required by the thyroid gland for thyroid hormone (TH) pro-
duction (for review see [86]). THs are necessary for the proper development
of the central nervous system (CNS), with an increased demand of iodine dur-
ing pregnancy [58, 120, 268, 72]. Severe hypothyroidism of the mother during
pregnancy may result in spontaneous abortion, stillbirth, congenital abnormal-
ities, and some forms of mental retardation, such as cretinism [85, 268]. The
severity and irreversibility of CNS damage is dependent on the degree of TH
abnormality, the time during development at which it occurs, and its duration.
The impact of mild or even subclinical hypothyroidism during pregnancy on
adult human behavior is still under discussion and was hypothesized to partic-
ipate as a predisposing factor in schizophrenia [293]. Because TH levels are
dependent, both on dietary supply of iodine and on genetically determined en-
zymes and other proteins that regulate TH metabolism, abnormal levels of THs
during critical periods of brain development could constitute a link between ge-
netic and environmental susceptibility factors. In other words, schizophrenia
may be associated with maternal thyroid deficiency at specific critical times
during gestation.
In addition to its involvement in the developing brain, significant disturbance
of thyroid function in the mature brain is known to profoundly alter mental pro-
cesses, including cognition and emotion. In the adult life, both hyperthyroidism
and hypothyroidism in severe forms have been associated with clinical symp-
toms of psychosis that frequently resemble schizophrenia [404, 403]. In par-
ticular, it has been shown that about 10% of hospitalized patients with acute
psychosis have some abnormality in thyroid function [405, 321].
In fact, several studies in schizophrenic patients have described altered TH
serum levels [315, 26, 229, 288, 307, 344]. Some reports have noted that TH
levels are increased only in the acute unmedicated phase of psychotic illness
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and decrease with the response to medication [26, 315, 415].
In order to further study the involvement of TH in schizophrenia, the present
study evaluates the thyroid function in chronic male schizophrenia patients and
compares them with mentally healthy individuals. To our knowledge, no such
study has so far been performed in the Portuguese population.
In particular, we measured serum levels of thyroid-stimulating hormone
(TSH), total and free thyroxine (TT4 and FT4), and total and free to triiodothy-
ronine (TT3 and FT3). TSH, produced in the pituitary gland, stimulates virtually
all steps of TH production. T4 is the main product of the thyroid gland. Although
a small percentage of T4 is converted to T3 within the thyroid gland most T3
in circulation is derived from extrathyroidal conversion of T4 in the peripheral
tissue, mostly in the liver and kidney [188]. Once released into circulation, T4
and T3 are rapidly bound to plasma proteins [314]. Less than 0.5% of the total
TH in circulation is in its free form [62].
7.2 Material and methods
Twenty one schizophrenic patients and 25 mentally healthy subjects were in-
cluded in this study. Ages are matched between cases (32.8±10.0) and con-
trols (29.7±6.8). All participants in the study were males with a European
ancestry. None of the participants had a known history of thyroid dysfunction,
but 8 of the patients (38%) reported a close relative (their mother in 4 cases)
with history of thyroid hormone disorders, while this was the case for only one
of the controls (4%).
All schizophrenic subjects were patients from the hospitals of Coimbra and
Braga, Portugal, and the study was approved by the respective ethic commit-
tees. All were receiving medication and seven (33.3%) were in crisis at the
time of the study, while 10 (47.6%) were in a stable phase. The average age
of onset was 19.1±5.4, ranging between 13 and 27 years old. The average
duration of the illness was 13.6±8.6 which ranges from 1 to 36 year.
All subjects in the study were evaluated using the Diagnostic Interview for
Genetic Studies (DIGS) [283], a semi-structured interview that assesses the
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criteria for schizophrenia and other psychiatric diseases. All patients where
then diagnosed as having schizophrenia according to Diagnostic and Statis-
tical Manual of Mental Disorders, review of the third edition (DSM-IIIR) crite-
ria [11].
After obtaining informed consent, blood was drawn from subjects, and the
serum was separated and frozen until hormone measurement. For assessing
thyroid hormone function serum measurements of TSH, TT4, FT4, TT3, and
FT3 were performed, using radioimmunoassay in accordance with the proce-
dure described in the manufacturer’s instructions (Diagnostic Products Corpo-
ration, LA, USA).
Student’s t-test was used to compare serum levels and age distributions
between patients and controls. In addition, this test was used to compare
serum levels between patient groups, when subdividing according to response
to neuroleptic medication, stable/crisis status at the time of study, and family
history of thyroid disease. The relationship between variables was analysed
using Pearson’s correlation coefficient. All tests were two-tailed and results
were considered to be significant if the P-value was less than 5%.
7.3 Results
All concentration levels measured fell within the considered normal range for
TH function. As shown in Table 7.1, the serum concentrations of TT4, FT4,
TT3, and TSH measured for patients were not significantly different from those
in the control group. In contrast, the FT3 serum levels were significantly lower
in schizophrenic patients.
When comparing TH serum levels between patients and their state of dis-
ease at the time of the study, the levels of TT3 were found to be significantly
(P-value=0.21) decreased in patients that were in crisis (107,3±14,2) with re-
spect to those that were stable (133,1±26,4).
Among schizophrenic subjects, no relationship was detected between serum
TH concentrations, age of onset, duration of illness, family history of thyroid
disease, or response to neuroleptic medication.
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Table 7.1: Age, serum concentration of TT4, FT4, TT3, FT3, and TSH.
N Mean±SD P-value
Total T4 (mg/dL) Cases 20 7.3±1.1 0.263
Controls 25 7.6±0.9
Free T4 (ng/dL) Cases 17 1.5±0.2 0.158
Controls 25 1.6±0.2
Total T3 (ng/dL) Cases 21 121±23 0.736
Controls 25 123±13
Free T3 (pg/dL) Cases 17 3.3±0.5 0.044
Controls 25 3.7±0.5
TSH (mIU/mL) Cases 20 1.5±0.8 0.211
Controls 25 1.3±0.4
7.4 Discussion
Though still within the normal range, the serum levels of FT3 were found to be
significantly decreased in our patients. Note that for most hormones “normal-
ity´´ is defined as a broad range of values, and several studies suggest that
significant difference between certain clinical groups may in fact reflect some
symptom or clinical feature of the disease. The control mechanisms by which
the hypothalamus-pituitary-thyroid axis regulates the production of TH by the
thyroid gland, are subtle and complex. Therefore, small fluctuations such as
those we found may still reflect or contribute to the schizophrenia manifesta-
tion.
The fact that in particular FT3 was found to be altered is interesting, since
THs exert their physiological effects mainly by binding of T3 to specific nuclear
receptors, which are ligand-dependent transcription factors. Furthermore, the
alteration of FT3 levels in particular is noteworthy because the concentration of
the free forms, rather than the total TH, is considered a more accurate indicator
of thyroid hormone-dependent activity in cells [314].
It is unknown how such subtle decrease of FT3 could impact TH function,
in particular the regulation of gene expression by T3, and lead to psychiatric
disorders such as schizophrenia. However among the genes whose expres-
sion is regulated by T3 are several that have been found decreased in schizo-
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phrenic brains, such as those encoding for myelin basic protein [317], and for
neurogranin [40] (discussed in Chapter 6).
Since most T3 is derived from deiodination of T4 within target cells [188], a
decrease in the T3 circulating fraction may reflect impaired deiodination. How-
ever, this might not be the case since no differences were found in serum
TT3 levels. It could instead result from altered tissue uptake or from abnormal
binding to serum carrier proteins.
Other studies also report euthyroid abnormalities in schizophrenia [315,
26, 229, 288, 307, 344]. Unfortunately, disease classification and treatment
differs between the studies and comparisons are therefore difficult to make.
Interestingly, some of these studies report that acute, unmedicated patients
have increased levels of TT4 and FT4 that decrease upon antipsychotic treat-
ment [26, 315, 415].
It is known that antipsychotic drugs may influence TH levels [95]. Do-
pamine and THs have many synergistic effects in many metabolic pro-
cesses [404]. Dopamine administration has been shown to rapidly decrease
TSH secretion [329, 176], and conventional antipsychotics, which are known
to act mainly by blocking various types of dopamine receptors, can inhibit TSH
secretion [415].
Serum levels of TT3 were found decreased for those patients that were
in crisis at the time of study. All patients in our sample are under chronic
treatment and, therefore, the observed TT3 decrease can not be attributed to
treatment, but may rather result from a particular feature of the disease. To
interpret this finding, the interaction between dopamine and TH might be rel-
evant. The CSF levels of dopamine metabolites has been shown to correlate
negatively, not only with TSH, but also with TT3 [354]. Thus, the observed TT3
decrease during crisis can be explained by increased dopamine transmission,
since such increase is known to induce schizophrenia symptoms.
The increased prevalence of thyroid disorders in relatives of schizophrenic
patients, as observed in our sample, has already been reported by others [74],
which further supports a possible link with the disease. Note that 4 of the 8 pa-
tients´ relatives with thyroid disorder in our sample, are their mothers. Interest-
ingly, recent studies have revealed that offspring of mothers who had TH de-
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ficiency during pregnancy, even if subclinical, showed significantly lower per-
formance in cognitive tasks when compared with matched controls [133, 179].
Intellectual dysfunctions have been documented to occur in schizophrenia pa-
tients even prior to the onset of psychosis [69].
An interesting extension of the preliminary study we reported here is to
include the mothers of the subjects into the study, and measure their thyroid
function. In this way, not only diagnosed thyroid disorders, but also mild and
subclinical hypothyroidism can be assessed. Such extended studies should
be conducted on samples of larger size, allowing subdivision for instance by
type of medication.
As discussed in the introduction, schizophrenia may be associated with
maternal thyroid deficiency during specific critical times in gestation. Presently,
our lab is conducting a study in pregnant women in whom TH function is evalu-
ated and related to the newborn’s psychodevelopmental performance. Follow-
up of these children might provide further insights into whether altered TH
function during pregnancy increases the risk for schizophrenia.
8
General discussion and future
perspectives
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In Chapter 1, we described the schizophrenia disorder and presented the
thyroid hormone (TH) and retinoid hypotheses, which fit in the commonly ac-
cepted view that schizophrenia is a neurodevelopmental disorder. These hy-
potheses say that TH and retinoid abnormalities during critical periods of neu-
rodevelopment could lead to brain alterations that give rise to schizophrenia
later in life.
In Chapters 3 to 6 we reported on association studies of four candidate
genes against the background of the TH and retinoid hypotheses. Our strat-
egy of investigation consisted of selecting candidate genes based on their
participation in the TH or retinoids pathways, and their involvement in func-
tions known to be abnormal in schizophrenia. In the remainder of this chapter,
we will give the rationale for the selection of each gene, and we will summa-
rize and discuss the relevance of the various results obtained (Sections 8.1
to 8.4). Subsequently, we will propose a hypothetical mechanism of action of
how a neurogranin variant could result in increased susceptibility to schizo-
phrenia (Section 8.5). We discuss how the results of the preliminary study
described in Chapter 7 could corroborate this mechanism. In Section 8.6, we
suggestion possible lines of future work.
8.1 Nur-related receptor 1 (NR4A2)
NR4A2 is an atypical member of the nuclear receptor superfamily that in-
cludes mostly ligand-activated receptors, like the retinoid and TH receptors,
which regulate gene expression via recognition of specific DNA-binding se-
quences [119, 200]. Unlike other nuclear receptors, NR4A2 does not seem to
need any ligand to activate the transcription of target genes [322], for which
reason it is called an orphan receptor. Retinoid X receptor (RXR) has been
shown to interact directly with NR4A2, by forming heterodimers, and to modu-
late its transcriptional activity [322, 295, 1].
The NR4A2 gene has been related with dopamine transmission known to
be abnormal in schizophrenia [84]. NR4A2 is highly expressed in dopamin-
ergic neurons of the midbrain [418, 328, 55]. Disruption of Nurr1 (the mouse
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homologue of NR4A2) revealed that its expression is essential for the forma-
tion of the dopaminergic system [418, 328], via regulation of dopaminergic
neuron-specific genes such as tyrosine hydroxylase [326, 185] and the dopa-
mine transporter [55, 24]. NR4A2 is also thought to protect dopamine neurons
against toxic insults, thus promoting their survival [204]. Due to its important
role in the modulation of the dopaminergic neurotransmission, NR4A2 may be
implicated in disease states where dopaminergic neurotransmission is dysreg-
ulated, such as schizophrenia. In fact, the 2q22-23 chromosome region that
harbors the NR4A2 gene has been suggested to be implicated in schizophre-
nia by linkage studies [260, 408, 75].
Several studies have failed to detect association between the NR4A2 gene
and schizophrenia [52, 168, 170]. However, given the well-established role
of NR4A2 in the formation of the dopaminergic system any mutation that al-
ters the function of this gene is expected to significantly impact brain function,
which can lead to mental illness such as schizophrenia.
Six rare variants have been described for the NR4A2 gene [44, 205, 60],
as shown in Figure 8.1. The mutations c.289A>G, c.308A>G and c.366-
369delTAC, found in schizophrenic and manic depressive individuals, originate
amino acid changes at the protein level and result in decreased transcriptional
activity of NR4A2 dimers [44]. Decreased transcriptional activity of NR4A2
is also described for two mutations (c.-291delT and c.-245T>G) in the 5´ un-
translated region found in patients with Parkinson’s disease [205]. The c.-
469delG mutation, in the promoter region, was found in schizophrenic patients
and its effect on gene transcription has not been determined [60]. Thus, these
mutations may be expected to impair proper function of NR4A2, leading to im-
paired transcription activity in its downstream target genes, such as tyrosine
hydroxylase and dopamine transporter.
We investigated the presence of these six variants in a Portuguese and in
a Brazilian sample (Chapter 3). None of the variants were found in any of the
schizophrenic patients or mentally healthy individuals.
The fact that the variants were not present in any of the 448 individuals
tested confirms that these mutations are indeed very rare. This absence also
implies that, in the Portuguese and Brazilian populations, none of the variants
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Figure 8.1: Genomic structure of the NR4A2 gene and positions of the six DNA variants an-
alyzed. Black boxes represent protein-coding regions and white boxes represent untranslated
regions. Locations of initiation (ATG) and stop (TAA) codons are also provided.
plays a major role in the etiology of schizophrenia. However, our negative re-
sults do not exclude the possibility that mutations on the NR4A2 gene could
account for high genetic susceptibility to schizophrenia in the particular indi-
viduals where the mutations were detected in the original studies.
Since altered expression of genes could result not only from DNA vari-
ants but also from inadequate supply of modulators of their transcription ac-
tivity [280], the fact that we failed to detect the presence of the studied DNA
variants in our samples does not exclude the possibility that the NR4A2 ex-
pression levels are altered in the brains of patients. In fact, data indicating
decreased expression in schizophrenic patients has been submitted to the
public genomic database of the Stanley Medical Research Institute [148]. Be-
low we will comment more elaborately on possible future work exploiting this
database information (Section 8.6).
8.2 Lipocalin-type of prostaglandin D2 synthase
(PTGDS)
The PTGDS protein is abundantly present in the cerebrospinal fluid
(CSF) [412]. The relation of PTGDS with THs and retinoids is reciprocal. On
the one hand, both regulate the expression of the PTGDS gene [175, 110,
109]. On the other hand, since PTGDS has been described as a transporter
for THs and retinoids [362, 31], abnormal levels of PTGDS can eventually dis-
turb their availability for modulating the expression of a large number of genes,
including PTGDS itself. In this way, PTGDS could contribute to the deleterious
effects of altered THs and retinoids in the central nervous system.
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Figure 8.2: Genomic structure of the human PTGDS gene and location of the four SNPs
detected. Black boxes represent protein-coding regions, white boxes represent untranslated
regions, and the dashed line represents the TH response element (TRE). Locations of initiation
(ATG) and stop (TAG) codons are also shown.
Several lines of evidence support that schizophrenic patients have altered
lipid metabolism [101], including decreased levels of arachidonic acid [414].
Arachidonic acid and its products (e.g. prostaglandins) are critical to various
signal transduction pathways [35]. The abnormal niacin response found in
schizophrenic patients [159, 393, 345] might be due to decreased levels of
arachidonic acid [101] or can result from abnormal activity of the enzymes
responsible for the synthesis of PGD2, whose epidermic release is involved in
the flushing response to niacin [271, 270].
The previous suggests the existence of abnormal prostaglandin signaling
in schizophrenia patients. In the brain, the formation of PGD2 is dependent
on PTGDS [375] and, interestingly, decreased levels of PTGDS have been
described in the CSF of schizophrenic patients [139, 137, 138].
For these reasons, we studied the association of PTGDS to schizophrenia
(Chapter 4). We first screened the exons, exon-intron boundaries, and the
promoter of the gene to detect DNA variants. The four detected and previously
described variants are shown in Figure 8.2.
Association studies were performed on three of the detected variants to
determine whether they predispose individuals to develop schizophrenia, us-
ing two case control samples from the Portuguese mainland and from Brazil,
and a parents-patient sample from the Azorean islands. The fourth variant
(rs7858965) was not included in the study since it is in complete LD with one
of the others.
None of the three variants was found associated to schizophrenia in any of
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our three independent samples. Thus, our data do no support the involvement
of the PTGDS gene in the schizophrenia etiology.
It remains to be verified whether the altered PTGDS levels detected in the
CSF of patients are a consequence of disease manifestation or induced by
antipsychotic medication. If these influences can be excluded, then the al-
tered levels of PTGDS may be attributable to inadequate supply of THs and/or
retinoids, which regulate the gene’s expression. In this case, PTGDS could
mediate the deleterious effect of TH and retinoids in the brain.
8.3 Transthyretin (TTR)
TTR is a major carrier of thyroxine (T4) and it binds to retinol through associa-
tion with retinol binding protein (RBP), both in the serum and in the CSF [292].
As a carrier of THs and retinoids, TTR indirectly mediates the transcription
of several of their target genes and, in this way, TTR may contribute to the
harmful effects of irregularities in their supply.
TTR has been implicated in behavior by observations that TTR-null mice
present increased motor activity in behavior tests addressing anxiety-like and
depression-like behaviors [349]. Furthermore, decreased levels of TTR in the
CSF were found in patients with depression [357] and with Alzheimer’s dis-
ease [337].
These considerations prompted us to study the association of TTR with
schizophrenia (Chapter 5). We screened the regulatory and coding regions of
the gene to detect DNA variants. The two variants detected, one of which we
described for the first time, are shown in Figure 8.3.
We studied possible association of the two variants in our two case control
samples from the Portuguese mainland and from Brazil, and a parents-patient
sample from the Azorean islands. We also analyzed the circulating levels of
TTR itself and of RBP.
Neither variant was found associated with schizophrenia in any of the three
independent samples. Thus, our data do not support the involvement of the
studied TTR variants in the schizophrenia etiology.
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Figure 8.3: Genomic structure of human TTR gene and locations of the two SNPs analyzed.
Black boxes represent protein-coding regions, white boxes represent untranslated regions.
Locations of initiation (ATG) and stop (TGA) codons are also provided.
Likewise, the measurements of serum levels of TTR and RBP did not reveal
any alteration associated to the disease.
Our results may seem to be in contrast with another study in which the
serum levels of RBP were found decreased in the serum of Chinese schizo-
phrenic patients from Singapore [409]. However, in that study, the RBP de-
crease was accompanied by a decrease of albumin. Since RBP is a useful
marker of protein malnutrition and both are inflammatory acute phase pro-
teins, the values observed in that study might reflect a particular nutritional or
inflammatory state in the patients, rather than schizophrenia manifestation.
It should be noted that serum levels of TTR do not necessarily reflect CSF
levels since serum TTR originates primarily from the liver, whereas CSF TTR is
mainly produced by and secreted from the choroid plexus [9]. In an early study,
CSF levels of TTR were found to be unaltered in schizophrenia patients [34].
Interestingly, after our study three further studies reported decreased levels
of TTR both in the blood [413, 155] and in the CSF [155, 388] of schizophrenic
patients. This discrepancy with the earlier negative results of CSF measure-
ments [34] could stem from the fact that the control group in this earlier study
consisted of patients with minor psychiatric problems, rather than mentally
healthy individuals.
The discrepancy of these three recent studies with the lack of alteration
found by us may stem from differences in medication. Patients medicated with
chlorpromazine were reported to have increased TTR serum levels compared
with drug-naı¨ve patients [388], while medication with clozapine was described
not to alter TTR plasma levels in patients [413]. Naı¨ve patients were consis-
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tently found to have decreased levels of TTR in CSF and serum [155]. Fur-
thermore, this last study reports decreased levels of TTR in prefrontal cortex
of medicated patients. The fact that we did not find decreased serum levels
of TTR may be attributable to the fact that our patients are under medication.
However, because medication programs are mixed, and different between pa-
tients, our data did not allow to appropriately differentiate groups of patients.
Future studies are needed to confirm the influence of medication in TTR ex-
pression. Evaluation of the levels of gene transcription in mice submitted to
various kinds of neuroleptic drugs could shed light on the matter. In particu-
lar, the effects of clozapine, reported not to affect TTR serum levels in schizo-
phrenic patients [413] but to induce TTR expression in the rat brain [59], should
be clarified.
One of the TTR polymorphisms we studied, ss46566417, had not been re-
ported before. This novel polymorphism is located on intron 3, 18bp upstream
of exon 4 of the gene. Since it is located near to a splicing site it may inter-
fere with transcription. For 100 individuals from our Portuguese and Azorean
samples, both genotype data and TTR serum level measurements were avail-
able. These individuals include cases and controls of both genders. We found
that the G allele was present in heterozygous form in 7 of these individuals
and that the level of TTR in this group was increased (331±50 versus 287±45
mg/L), with a borderline significance (P-value=0.059). The homozygous form
was not present. Due to the low frequency of the G allele, a larger sample
size is needed to confirm this tendency. The larger sample should also allow
stratification by gender and by phenotype. Thus, a future study on a larger
scale could confirm whether the G allele of this novel SNP indeed increases
expression of TTR.
8.4 Neurogranin (NRGN)
The neurogranin (NRGN) gene encodes a postsynaptic brain-specific protein
and its expression is regulated by THs and retinoids [93, 130, 161, 165].
NRGN binds calmodulin (CaM) with high affinity [108, 300, 303]. By regu-
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Figure 8.4: Genomic structure of the human NRGN gene and positions of the three SNPs
tested and of the mutation found. Black boxes represent protein-coding regions, white boxes
represent untranslated regions, and the dashed line represents the TH response element
(TRE). Locations of initiation (ATG) and stop (TAG) codons are also provided.
lating the release of CaM, NRGN indirectly regulates the expression of CaM-
Ca2+-dependent enzymes that play an important role in the neuroplasticity
mechanisms of learning and memory [157, 291]. The stimulation of N-methyl-
D-aspartate (NMDA) receptors by glutamate induces dissociation of the NRGN-
CaM complex. Therefore, altered NRGN activity could mediate the effects of
NMDA receptor hypofunction suggested by several studies to be implicated in
schizophrenia [368]. Moreover, the NRGN chromosome region has previously
be implicated in schizophrenia by linkage studies [132].
These considerations prompted us to investigate the involvement of the
NRGN gene in the schizophrenia etiology. We screened the exons and adja-
cent splicing sites, as well as the TH response element (TRE) on intron 1 of
the NRGN gene to detect DNA variants. We detected a new single-nucleotide
variant (c.-71C>T) and two previously described SNPs. These variants are
shown in Figure 8.4, together with a third SNP obtained from the NCBI SNP
database.
We studied association of the three SNPs of NRGN with schizophrenia
in our three samples (Chapter 6). Because of its very low frequency, the c.-
71C>T variant was not included in the association study. For two of the three
variants studied (rs1804829 and rs12541), no association to schizophrenia
was found in any of the three samples.
For males of Portuguese origin, genotype distribution showed association
of the rs7113041 polymorphism to schizophrenia, and this result was con-
firmed in the Azorean patient-parents triads. More specifically, we found a
significant excess of the CG genotype in Portuguese males (P-value=0.029,
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n=297), with this genotype predisposing for the disease. For males in the
smaller Brazilian sample, the same tendency was observed but without reach-
ing statistical significance (P-value=0.065 with n=145). In the Azorean patient-
parents sample, under-transmission was found for the GG genotype, both in
the overall sample (P-value=0.039, n=70) and in the male-patient subsample
(P-value=0.014, n=46), but not in the female-patient subsample. Analysis of
the three samples combined strongly confirmed genotype association of the
rs7113041 polymorphism to schizophrenia in males.
Confirmation of our result in further independent samples, stratifiable by
gender, is of prime importance.
The gender specificity of the association is of particular interest since sig-
nificant symptomatic differences between sexes have been observed in schizo-
phrenia. As mentioned in Section 1.1.1 schizophrenia presents a gender bias
in age of onset, severity of clinical course, and response to antipsychotic
drugs. Males show more negative symptoms and cognitive deficits [208].
These gender-specific phenotypic differences may reflect distinct genetic com-
ponents in disease etiology. In fact, the gender bias found is not unprece-
dented, since other association studies in schizophrenia reported associa-
tion of female gender with DNA variants of the DISC1, ZDHHC8, and COMT
genes, and of male gender with another variant of COMT [342, 273, 145].
Given NRGN’s involvement in cognitive functions [157, 291], the associa-
tion we found of the rs7113041 SNP with schizophrenia in males could explain
the observation of more cognitive deficits in male patients. To explore this hy-
pothesis, larger samples, stratified by several disease features, will be needed
to investigate whether the association found is due to some specific symptom.
Another line of future study is warranted to clarify the influence of the G
allele of the rs7113041 variant on the expression of NRGN in brains of schizo-
phrenic patients. The implicated SNP rs7113041 could influence the transcrip-
tion of the NRGN gene by interfering with the binding of the TH receptor to its
DNA response element. To investigate this possible influence on gene expres-
sion, postmortem studies are needed that correlate NRGN expression levels
in patient brains with their rs7113041 genotype. Both genders should be in-
cluded in the study to establish whether the altered gene expression, if found,
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is sex-dependent.
The c.-71C>T variant of the NRGN gene, found in one heterozygous indi-
vidual among 60 cases screened, had not been reported before. Due to its low
frequency this mutation was not included in the association study, but it was
genotyped separately in the samples from the Portuguese mainland and from
Brazil. After genotyping, the mutation was identified, in heterozygous form,
in 2 out of 313 cases (244 Portuguese mainland and 69 Brazilian) and was
absent from the 295 controls (210 Portuguese mainland and 85 Brazilian).
The fact that the mutation was found only in patients suggests that in the
families of these two individuals this mutation could play a role in the etiology
of schizophrenia. Therefore, we directed our attention to the relatives of these
two individuals, in which the mutation is likely to occur with higher frequency
than in the general population. The fact that the healthy mother of one patient
was found to carry the mutation, rules out that presence of this mutation is suf-
ficient for schizophrenia development, but is inconclusive regarding a poten-
tial causative effect in the context of a multifactorial etiology of schizophrenia.
Screening of additional relatives might be essential to clarify the implication of
the mutation in the schizophrenia disorder, but, unfortunately, none have so far
been localized.
NRGN and the glutamatergic hypothesis of schizophrenia
NRGN joins several other genes already implicated in schizophrenia that are
likewise involved in the glutamatergic pathway, such as dysbindin and neureg-
ulin. Thus, our finding introduces an additional player into the glutamatergic
hypothesis of schizophrenia.
Analysis of the glutamatergic transmission places NRGN in the center of
the glutamatergic pathway. Figure 6.2 in Chapter 6 summarizes the relation-
ship of NRGN with the glutamatergic hypothesis of schizophrenia. On one
hand, NRGN is a downstream target of glutamatergic transmission. Thus the
hypofunction of the NMDA receptor present in schizophrenia will impair NRGN
phosphorylation/oxidation. On the other hand, by regulatiing intracellular lev-
els of Ca2+ and CaM-Ca2+, disruption of NRGN homeostasis will alter postsy-
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naptic signal transduction pathways, which are regulated by these secondary
messengers.
Interestingly, schizophrenic postmortem brains have altered expression lev-
els of CaM-Ca2+ target genes. While PKC [71], calcineurin [87] and 14-3-
3 [249] were found decreased in the temporal lobe, hippocampus, and pre-
frontal cortex, respectively, CaMKII levels were found increased in the pre-
frontal cortex of schizophrenic brains [281]. This can be a consequence not
only of the NMDA receptor hypofunction but also of the reduced NRGN lev-
els [40]. Altered NRGN activity could ultimately result in the dendritic and
spine loss described in schizophrenia [279, 10] as suggested by Broadbelt
and collaborators [40].
An interesting feature in the relation between glutamatergic neurotransmis-
sion and schizophrenia that can be explained at least in part by NRGN func-
tion, is the observation that the psychotomimetic effects of NMDA antagonists
are minimal or absent in children but become apparent in late adolescence
and early adulthood [402], the time when schizophrenia symptoms typically
have their onset. This could reflect a direct influence of hormonal status in
the NMDA receptor or in any of its downstream effectors, like NRGN; which is
supported by the age-related down-regulation of NRGN expression observed
in rodents [266]. In addition, several modulators of NMDA receptor activity,
implicated in schizophrenia, could exert their effect, at least in part, by altering
NRGN activity. Among these are dysbindin, neuregulin, D-amino acid oxidase
activator (DAOA), and regulator of G-protein signaling 4 (RGS4), all strong
candidates in the pathophysiology of schizophrenia [142].
8.5 A hypothetical causative mechanism
As suggested by linkage studies, schizophrenia possibly results from the effect
of several genes each conferring only a small increase in disease susceptibil-
ity. It is also plausible that their small contributions become important only
under certain environmental conditions.
We make the case here that low levels of THs and retinoids during critical
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Figure 8.5: Hypothetical causative mechanism of how the rs7113041 polymorphism of
NRGN may increase schizophrenia susceptibility. Under thyroid hormone (TH) deficiency, the
common C allele of the rs7113041 polymorphism does not compensate the reduced transcrip-
tion of the gene, provoked by the presence of the G allele, which interferes with the binding
of the TH receptor to the TH response element (TRE). The decrease of NRGN levels result in
disturbed glutamate transmission, leading to abnormal neurodevelopment, which may predis-
pose to manifestation of schizophrenia later in life, possibly under the presence of additional
environmental factors.
periods of brain development could interact with DNA variants in susceptibility
genes to affect brain development negatively and give rise to schizophrenia
later in life.
As we discussed before, the rs7113041 SNP of the NRGN gene could in-
terfere with the binding of the TH receptor to the DNA response element and
subsequently influence the transcription of the NRGN gene. Decreased ex-
pression of NRGN could seriously affect the glutamatergic transmission, lead-
ing to neurodevelopmental abnormalities which could consequently increase
the risk to develop schizophrenia. The significant excess of the CG genotype
in patients found in our study, with this genotype predisposing for the disease,
could be explained by the possibility that the minor allele (G) of the rs7113041
SNP hampers binding of TR, thus inhibiting NRGN expression. This hypothet-
ical mechanism is depicted in Figure 8.5. Note that individuals with the CG
genotype who experience TH deficiency only when neurodevelopment has
been completed may suffer abnormalities in CNS function through a similar
decrease of NRGN transcription and the consequent disturbance of glutamate
transmission.
The rs7113041 heterozygous genotype is also common in the general pop-
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ulation. This is not surprising, if we assume that, in addition, TH levels are
decreased during development of individuals who later develop schizophre-
nia. With normal levels of TH, the hampering effect of the G allele would be
diluted by the presence of the normal C allele. But, when TH levels drop and
general transcription slows down, the single C allele might fail to compensate,
with subsequent decrease in NRGN expression.
Measurement of NRGN levels in postmortem brains, suggested above in
order to investigate the influence of the G allele on gene expression, could
shed light on this hypothesis. Note that, in case such study does not reveal
altered expression, the rs7113041 variant may still be of influence on NRGN
expression under decreased TH levels. To address this second possibility,
in vitro studies should be conducted with cells in which reporter genes are
introduced. By subjecting the cells to different levels of TH, their influence
on gene expression in the presence of the C and G alleles of the rs7113041
polymorphism can be tested.
This hypothetical causative mechanism of how the rs7113041 polymor-
phism of NRGN confers susceptibility to schizophrenia can not explain that
we found association to schizophrenia in males only, unless differences in TH
regulation exist between the sexes. In Chapter 7, data of preliminary measure-
ments of TH levels in circulation revealed decreased levels of free T3 in male
patients compared with controls. If these measurements in adults would reflect
decreased levels during gestation, they would support our hypothesis. Addi-
tionally, this data, when combined with the NRGN genotyping data, reveal that
free T3 levels are decreased in male CG cases versus male CC cases, but
that no such decrease is found for male controls. This observation likewise
seems to support that the rs7113041 polymorphism could reduce expression
of the NRGN expression under TH deficit, and thus increase schizophrenia
vulnerability.
If in fact the G allele of the rs7113041 variant is associated with the de-
creased expression of NRGN, then the G homozygous will be selected against
due to the low levels of NRGN. This would explain why the GG genotype is so
rare. Only individuals with sufficiently high levels of THs would still be able
to have minimally sufficient NRGN expression. This low frequency of the GG
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genotype could also explain why, in our studies, we found this genotype to be
protective rather than predisposing to schizophrenia.
In conclusion, under the hypothetical mechanism presented here, NRGN
seems to provide an example of a gene-environment interaction with causative
effects in the etiology of schizophrenia. Previously, the APOE and HOPA
genes have been suggested as other examples of such gene-environment
interaction.
APOE has been shown to increase susceptibility to schizophrenia in in-
dividuals subjected to fetal or early post-natal malnutrition [213], although it
is not known whether the increased predisposition arises from a global nutri-
tional deficiency or from a specific micronutrient deficiency. The latter seems
to be the case, since APOE has also been shown to be a genetic risk factor for
iodine deficiency disorders [218, 390] in regions with abnormally low supply of
iodine [389]. Interestingly, the APOE gene has a T4 binding domain, and it
possibly mediates the binding of T4 to low-density lipoproteins (LDL) [29]. In
addition transcription of APOE has been shown to be upregulated by T3 [378].
In conclusion, it seems valid to speculate that APOE, like NRGN, may confer
increased risk to schizophrenia specifically under TH deficiency.
Recently the HOPA gene has been associated with an increased suscep-
tibility to both schizophrenia and hypothyroidism [76, 297, 186, 296]. This as-
sociation provides a possible genetic mechanism for the familial aggregation
of thyroid function abnormalities and schizophrenia. The HOPA gene encodes
a 230 kDa subunit of the TH-associated protein (TRAP) complex [169] which
is responsible for tissue-specific transcription regulation [420, 258].
8.6 Future perspectives
In this section, we discuss ongoing and future lines of research.
8.6.1 Association studies
Association studies are a powerful tool to detect genes of small effect in dis-
ease susceptibility. With the objective of investigating whether retinoids and
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THs are related to the pathophysiology of schizophrenia, we have performed
association studies for four genes with various roles in the pathways and
modes of action of THs and retinoids. For NR4A2, TTR, and PTGDS, we
found no association to schizophrenia, but in the case of NRGN, association
was found between the G allele of a particular variant with schizophrenia in
males.
The decreased levels of free T3 for which we detected a tendency in male
patients indicates that further association studies are warranted for instance
for genes encoding enzymes responsible for the regulation of T3 levels. In
particular, it seems promising to evaluate the association of type II deiodinase
(DIO2) and type III deiodinase (DIO3), genes whose proteins regulate forma-
tion and degradation of T3 in the brain (see also Section 1.2.4). Such studies
are ongoing.
8.6.2 Expression studies
Association studies are an appropriate instrument to search for causal rela-
tionships between particular gene variants and disease manifestation. How-
ever, changes in gene expression underlying schizophrenia may result not only
from variants in the DNA sequence of genes, but also from abnormal supply
of modulators of the transcription activity of genes with unchanged DNA se-
quence [280]. This line of investigation was not included in the scope of the
work reported in this thesis, but will be the subject of future studies.
The TH and retinoids hypotheses of schizophrenia involve exposure to ab-
normal levels of these elements during early stages of neurodevelopment.
However, study of material harvested in early life, such as maternal serum
and dried blood spots, meets with many practical obstacles, since it relies
on banked specimens hard to obtain in sufficient quantity. Still, vestiges of
alterations may remain in adult brain and provide clues on developmental im-
pairments.
With the purpose of studying the expression of TH and retinoids genes in
human brain material and lymphocytes, a microarray study has been designed
and a corresponding platform is presently being constructed. The study in-
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cludes genes that influence the level of THs and retinoids, genes than encode
for TH and retinoid nuclear receptors, and genes whose expression is regu-
lated by THs and retinoids.
The inclusion of lymphocytes in the study has several distinct advantages.
Though blood can certainly not be regarded as a perfect reflection of the brain,
recent evidence clearly shows that lymphocytes can at least partially repre-
sent or mimic brain dysregulation [117, 248]. Thus, lymphocytes can to some
extent be used as an alternative to postmortem brain tissues, allowing for in-
stance the screening of gene expression in drug naı¨ve patients. The use of
lymphocytes has the additional advantage that the material is easy to collect
and any alteration found might eventually lead to a molecular diagnosis of the
disease.
Recently, data from 12 microarray studies using brain tissues of patients
with various mental illnesses, including schizophrenia, have been collected
and made available in the online genomics database of the Stanley Medical
Research Institute [148]. This database contains rich clinical information and
gene expression patterns. In 11 of the 12 controlled studies, brains of schizo-
phrenic patients were analyzed. The percentage of genes included in these
11 studies for which significantly altered expression was found amounted to
2.5%, considering an alteration to be significant if the P-value was less than
5%. This percentage drops to 0.8% when significance is accepted when the
P-value is smaller than 1%.
We have retrieved information from this database for 176 of the genes in-
cluded in the TH and retinoids microarray. For 49 out of the 176 genes, altered
expression was detected, considering a P-value smaller than 5%. Out of those
49, a set of 8 genes was detected to have significantly altered expression even
under P-value less than 1%. Thus, at these levels of significance, altered ex-
pression was detected in 27.8% and in 4.5%, respectively, of all 176 genes.
These markedly higher percentages, with respect to the percentages for all
genes found altered in schizophrenia, corroborate the hypothesis of abnor-
mality of these metabolisms in schizophrenic patients.
Out of the 8 genes most likely to be altered, 5 are downregulated: early
growth response 1 (EGR1); aldehyde dehydrogenase 1 family, member A2
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(ALDH1A2); mitogen-activated protein kinase kinase 4 (MAP2K4); nur-related
receptor 1 (NR4A2); and retinoic acid receptor, beta (RARβ). The remain-
ing 3 genes are upregulated: lipoprotein lipase (LPL); RAR-related orphan
receptor A (RORA); and tumor necrosis factor receptor superfamily, member
6 (TNFRSF6).
To confirm the alterations in the 49 genes, the microarray measurements
need to be reproduced using a more sensitive and more accurate method of
relative gene expression measurement, such as quantitative real-time poly-
merase chain reaction (RT-PCR). Such studies are currently under way for the
set of 8 genes most likely to be altered. Apart from measuring gene expres-
sion, the levels of protein should also be measured because altered mRNA
expression levels do not always lead to altered protein levels. This can be
done using techniques such as immunohistochemistry in brain material.
For each gene for which altered expression is confirmed it must be clari-
fied whether the alteration is the result of pharmacological intervention. This is
especially important, since studies have shown that antipsychotic drugs seem
to be capable of regulating TH and retinoid signaling pathways [196, 97]. Ex-
periments with rodents submitted to different medication programs can help
to address this issue. Gene expression measurements should be performed
before and after administration of medication to conclude on the effect of each
neuroleptic drug. These experiments are ongoing.
8.6.3 Epistasis
The basic strategy underlying most studies that aim to identify genetic risk
factors for complex traits focus on individual loci which are assumed to con-
tribute with small, additive effects to the phenotype. The studies reported in
this thesis are no exception. However, given the limited number of genes in the
human genome, it seems reasonable to assume that non-additive, or epistatic,
interactions between genes contribute considerably to the inter-individual phe-
notypic variation [316]. Indeed, geneticists are increasingly aware of the
possibility that gene-gene interactions are important determinants of complex
traits [220, 224].
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In fact, as pointed out in Chapter 1, the risk of developing schizophrenia,
which decreases rapidly as the degree of genetic relatedness decreases, is
compatible with a model of multiple loci with epistasic interaction between
them. Since the various genes involved in the TH and retinoid metabolisms
are biologically, functionally, temporally or spatially related, it is possible that
they interact epistatically. This line of research merits future exploration.
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